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Abstract
Alzheimer’s disease (AD) is a degenerative neurological disorder characterized by
cognitive and functional impairment (Budson & Solomon, 2011). Its prevalence is expected to
rise in the upcoming decades as the world’s population ages (Alzheimer’s Association, 2014).
Amnestic mild cognitive impairment (MCI) is a clinical diagnostic entity that may represent very
early AD (Morris et al., 2001). Both disorders involve significant impairment in episodic
memory, necessitating reliable memory measures when making diagnoses. Although verbal
memory is most often impaired in the earliest stages of disease (Budson & Price, 2005), visual
memory is also predictor of AD (Kawas et al., 2003). Partly due to a lack of comparative data
between visual memory measures, they are often chosen based on clinical rather than
psychometric needs. This study compared several commonly-used visual memory measures in
order to provide data to which clinicians can refer when choosing between measures when time
is limited.
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A 2 × 8 mixed within-between groups design was used to compare measures in a group
of 20 older adult patients at a memory disorders clinic diagnosed with AD or MCI and in a
comparison group 20 normal healthy controls. Subtests from the Wide Range Assessment of
Memory and Learning, 2nd Edition (WRAML2; Sheslow & Adams, 2003), the Wechsler
Memory Scale, 4th Edition (WMS-IV; Wechsler, 2009), and the Brief Visuospatial Memory
Test, Revised Edition (BVMT-R; Benedict, 1997) were administered to each participant as part
of a comprehensive test battery. Correlations between measures were stronger in the control
group (r =-.335 to .871, mean r = .157) than in the control group (r = -.421 to .825, mean r =
.289). Mean scaled scores differed significantly between groups on most measures, with large
effect sizes (d = 1.26 to 2.77, mean d = 1.815). Differences in mean scaled scores between some
measures were larger in the clinical group than in the control group. Results demonstrate
convergent validity between measures despite differences in item content and response format.
Certain measures demonstrated psychometric characteristics that may be advantageous
depending on the clinical setting.
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Chapter 1
Introduction
Memory
A quote attributed to Endel Tulving, one of the best-known researchers in the field of
memory, states, “Remembering, for the rememberer, is mental time travel.” Memory is at once
fundamental to the conscious experience of existence as well as enormously complex,
underpinning almost all of the most important aspects of what it means to be human. It is, in a
phrase, the process by which we store the information that allows us to create meaning in the
world. Because of its complex interrelationships with so many cognitive processes, memory
represents one of the most challenging pursuits in psychological research. Accordingly, it has
been a subject of study not only from the time when psychology was a nascent science, but also
from the dawn of history (Jaynes, 1976).
Ebbinghaus (1913) is memorialized as the first scientist to systematically evaluate
memory processes in a human subject—himself. He created the idea of a forgetting curve, and
provided quantification of the rate of forgetting with the passage of time. Karl Lashley induced
brain lesions in laboratory animals in search of the engram, the name he gave to the hypothetical
unit of memory storage; he concluded, having failed to find it, that memories are stored diffusely
throughout the cerebral cortex (Eichenbaum & Cohen, 2001). In the 1960s, Atkinson and
Shiffrin (1968) developed what they called the multi-store model of memory that is comprised of
sensory, short-term, and long-term memory. Shortly after the publication of Atkinson and
Shiffrin’s model, Tulving (1972) clarified the difference between episodic and semantic

Running head: TESTS OF VISUAL MEMORY

2

memory. Taken together, these theories have been extraordinarily influential in our
understanding of the hippocampus, the subcortical structure whose primary function is to encode
sensory information into short-term memory stores and then consolidate it into long term
memory to be stored elsewhere in the brain (Milner, Squire, & Kandel, 1998).
Changes in memory occur as part of the normal aging process (Cullum, Butters, Tröster,
& Salmon, 1990). Episodic memory, in particular, is susceptible to impairment when age, injury,
or illness disturbs the normal functioning of the human brain.
Memory and Aging
The ancient Greeks, and Socrates in particular, were aware of the ways in which memory
may decline in old age (Berchtold & Cotman, 1998). They, and most of their intellectual
descendents, misattributed the proximal cause of memory decline to advancing age. Hardly
anyone born before 1900 could expect to live much beyond the age of 65. It was therefore
difficult for ancient and pre-modern scientists to compare normal and abnormal memory
functioning in the oldest old because the base rate of survival was so low. Until well into the
20th century, most people believed that cognitive decline was an inevitable side effect of the
aging process. We now know this to be false.
A decline in memory does not necessarily indicate the presence of pathology. V. A. Kral
(1962) was the first researcher to classify senescent forgetfulness as either benign or malignant.
While many people experience a change in cognition as they age, the change is only sometimes
due to a disease process; age itself is not a disease. Kral hypothesized that age-related cognitive
changes may be due to a mild degree of general cortical atrophy that progresses slowly over
time, in the absence of the severity of hippocampal atrophy that is seen in degenerative
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neurological disorders. Kral’s benign senescent forgetfulness is now more frequently called ageassociated memory impairment (AAMI). In support of Kral’s theoretical stance, Walhovd and
colleagues (2005) demonstrated that age-related volumetric changes in the hippocampus are
curvilinear over the lifespan, first growing and then shrinking with increasing age.
Malignant senescent forgetfulness, in the presence of certain diagnostic criteria (see
Appendices A and B), is now called major neurocognitive disorder or dementia. Dementia is a
general term that implies a deviation from the normal aging process (Grundman et al., 2004). In
the lay public, dementia is used synonymously with Alzheimer’s disease (AD). While AD is the
most common cause of dementia in people over the age of 65 (Budson & Solomon, 2011), it is
only one of the dozens of known causes of dementia.
Alzheimer’s Disease
Alois Alzheimer’s description of Auguste Deter, Über eine eigenartige Erkrankung der
Hirnrinde (“Regarding a peculiar illness of the cortex,” 1907; Stelzmann, Schnitzlein, &
Murtagh, 1995), has been immortalized in the literature as the index case of his eponymous
disease (Berchtold & Cotman, 1998). Using a microscope, the most sophisticated method of
evaluation at the time, Alzheimer documented post-mortem histopathological evidence of
amyloid plaques and neurofibrillary tangles in the brain of a woman who died in her early 50s.
Only a century later did Müller and colleagues (Müller, Winter, & Graeber, 2013) demonstrate
that hers was a case of a very early-onset, autosomal-dominant form of AD that is extraordinarily
rare in the general population. Nevertheless, Alzheimer’s findings became the definitive metric
by which the idiopathic form of AD, the kind most commonly seen in older adults with
progressive memory decline, is diagnosed.
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AD is a degenerative disease that represents a departure from typical aging. By current
estimates, more than 5 million Americans currently have AD (Alzheimer’s Association, 2014);
of those 5 million, up to 50%, or 2.5 million, have not been diagnosed. The Alzheimer’s
Association estimates that by 2050 there may be as many as 1 million new cases of AD per year,
adding up to a prevalence of almost 14 million in the United States alone. Of the leading causes
of death in the United States, AD is the 6th overall, and the 5th in people over the age of 65.
Concurrent with a decrease in the proportion of deaths resulting from heart disease, stroke, and
prostate cancer in the decade ending in 2010, there was a 68% increase in the proportion of
deaths resulting from AD. The estimated cost of treating people over the age of 65 with
Alzheimer’s disease is expected to rise to $214 billion per year in 2014, an increase of 5% from
the previous year; this does not include the estimated contributions of more than 15 million
unpaid caregivers, whose time and efforts were valued at $220 billion in 2013 (Alzheimer’s
Association, 2014).
Clearly, AD is an important public health issue in a country with almost 40 million
inhabitants who are older than 65 (American Psychological Association, 2012). In the scientific
community, research has focused on the increasingly early detection of AD with the hope that
intervening at a very early stage in the disease process may prevent some of the symptoms that
eventually develop as AD progresses. Because memory is one of the first cognitive domains in
which decline is evident in AD patients, the early detection of memory impairment is a crucial
step in identifying cases of AD in order to manage the societal—and especially the personal—
damage that AD can cause.
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Pathophysiology of AD: The Amyloid Cascade Hypothesis, Amyloid-β, and Tau
The amyloid precursor protein (APP), which is present in the membranes of neurons, is
normally cleaved by alpha- and gamma-secretase, and the byproducts are cleared by
cerebrospinal fluid (CSF; Querfurth & LaFerla, 2010). When APP is cleaved by β-secretase
before being cleaved by γ-secretase, however, a monomeric peptide composed of 40–42 amino
acids called amyloid-β is produced. The biological role, if any, of amyloid-β is unknown,
although a suggestion has been made that it may be an antimicrobial molecule (Soscia et al.,
2010). For reasons that are not fully understood, amyloid-β monomers tend to join together to
form dimers that gather into oligomers, which are toxic to cells and are not easily cleared by
CSF. The buildup of amyloid-β oligomers leads to the formation of amyloid plaques, which also
contain the detritus of dead cells. Amyloid plaques interfere with synaptic transmission between
neurons. In addition, they are thought to cause the hyperphosphorylation of τ (tau), a protein that
is present in the microtubules of neuronal axons. In its normal form, τ provides structure to the
microtubules. When hyperphosphorylated, however, τ causes the microtubules to twist into
paired helical filaments. Neurons die off due to impaired intracellular nutrient transport, and the
axons of these dead cells containing hyperphosphorylated τ form neurofibrillary tangles.
Amyloid plaques and neurofibrillary tangles accumulate predominantly in the
hippocampus, the temporal lobes, and the parietal lobes, leading to the characteristic cognitive
changes associated with Alzheimer’s disease: memory impairment, word-finding difficulty,
spatial confusion, and disorientation (Budson & Price, 2005). The pathophysiological process
associated with cognitive symptoms is believed to begin 10 to 20 years before symptoms are first
noticed by patients or family members (Budson & Solomon, 2011).
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Acetylcholinergic neurons are a particular target of this degenerative process. As these
cells die in increasing numbers, post-synaptic acetylcholine receptors upregulate in order to
compensate for the decrease in acetylcholine at the synapse. Meanwhile, acetylcholinesterase, an
enzyme that is partially responsible for the removal of acetylcholine from the synapse, remains
active, limiting the availability of acetylcholine at post-synaptic receptors. Acetylcholinesterase
inhibitors are thought to be therapeutic due to their action at the synapse, intensifying neuronal
transmission by reversibly (i.e., temporarily) inhibiting the breakdown of acetylcholine (Rogers,
Farlow, Doody, Mohs, & Friedhoff, 1998). As neurons continue to die, compensatory
mechanisms begin to fail, leading to an increasingly rapid decline in cognition and function.
Alzheimer’s disease is almost always fatal, usually within 6-8 years of diagnosis (Budson &
Solomon, 2011), typically due to complications that arise from functional impairment, such as
bedsores, pneumonia, aspiration, or falls.
Diagnosis of AD
Several diagnostic frameworks have been used to diagnose AD; in general, they all share
the same core criteria: a progressive decline in memory along with impairment in one other
cognitive area and the presence of functional decline (i.e., impairment in activities of daily
living). It is important to note that while all cases of AD are dementias by definition, not all cases
of dementia are due to AD; only around 70% of dementias are due to AD (Budson & Solomon,
2011). In addition, all clinical diagnoses of AD should be considered diagnoses of exclusion;
although the biomarkers discussed below can add certainty to clinical judgment, the final
diagnosis is made by histopathological analysis on autopsy.
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In 1984, the National Institute of Neurological and Communicative Disorders and Stroke
(NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) published
diagnostic criteria for Alzheimer’s disease (McKhann et al., 1984). The resulting NINCDSADRDA criteria allowed for the diagnosis of possible or probable AD, with disease stage
classified as early (mild), middle (moderate), and late (severe) depending on cognitive and
functional impairment. The Diagnostic and Statistical Manual of Mental Disorders, 4th Edition,
Text Revision (DSM-IV-TR; American Psychiatric Association, 2000) uses the term Dementia
of the Alzheimer’s Type (DAT) in describing the symptoms of the cognitive and functional
impairment that constitute the syndrome (Appendix A). In 2011, the National Institute on Aging
(NIA) and the Alzheimer’s Association (AA, formerly known as the ADRDA) published a new
set of guidelines in three parts (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011)
as an update to the NINCDS-ADRDA criteria. The NIA-AA criteria provide for the diagnosis of
MCI due to the AD pathophysiological process. Two additional stages on the AD spectrum were
added: presymptomatic/prodromal/preclinical AD and symptomatic but non-demented AD (i.e.,
MCI). The new guidelines also encourage the use of biomarkers, such as CSF analysis and
amyloid positron emission tomography (PET), to increase the accuracy of the diagnosis of
preclinical AD (Budson & Solomon, 2012). A summary of the new guidelines can be found in
Appendix B. New criteria for Major and Minor Neurocognitive Disorder in the DSM-5
(American Psychiatric Association, 2013) closely resemble the NIA-AA diagnostic criteria and
appear to have properly conjoined the disparate diagnostic criteria promoted by various medical
specialties into one cohesive framework. These criteria are summarized in Appendix C.
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AAMI, Mild Cognitive Impairment, and the AD Continuum
Larrabee, Levin, and High (1986) demonstrated evidence in support of age-associated
memory impairment (AAMI) as a clinical entity that is distinct from what, at the time, was called
senile dementia. In a sample of 88 normal controls between the ages of 60 and 90, they found
that between 10% and 20% of the sample exhibited memory impairment beyond what would be
expected for their age but in the absence of other cognitive impairment. These participants
nevertheless performed better overall than a group of AD patients. While the authors conclude
that their data support Kral’s (1962) concept of benign senescent forgetfulness, it is important to
note that the idea of mild cognitive impairment was not widely endorsed by memory researchers
of that era. It is therefore difficult to determine whether the participants with so-called AAMI
may have demonstrated the degree of memory impairment that would earn a diagnosis of MCI
today.
There is growing consensus that mild cognitive impairment (MCI) represents a very early
stage of AD (Albert et al., 2011; Morris et al., 2001), in which memory impairment is present in
the absence of functional impairment. Patients with MCI and AD have similar patterns of
memory impairment, and non-memory measures (e.g., ADLs) better distinguish one from the
other (Jacova, Kertesz, Blair, Fisk, & Feldman, 2007). At times the distinction between the two
is made on clinical rather than psychometric grounds, and the treatment for both is similar
(Budson & Solomon, 2011).
Memory Testing: Verbal and Visual
Neuropsychological testing is a critical part of the diagnosis of AD (McKhann et al.,
1984; McKhann et al., 2011; Smith & Bondi, 2013). The American Psychological Association,
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in its Guidelines for the Evaluation of Dementia and Age-Related Cognitive Change (2012),
declared that “Psychologists are aware that standardized psychological and neuropsychological
tests are important tools in the assessment of dementia and age-related cognitive change” (p. 2).
AD impairs both encoding (short-term to long-term memory storage) and retrieval (Budson,
Wolk, Chong, & Waring, 2006). Memory impairment is one of the earliest sign of impending
AD/dementia (Jacova et al., 2007) and “episodic memory tests appear to have the greatest
predictive accuracy” (p. 311). For various reasons—perhaps in particular due to the relative
stability of verbal memory with normal aging (Cullum et al., 1990; Giambra, Arenberg, Kawas,
Zonderman, & Costa, 1995; Salthouse, 2010), as well as the fact that anomia is a prominent early
feature of AD (Budson & Price, 2005) and the importance of verbal communication in modern
society—verbal memory has been a consistent focus of study in the dementia literature.
However, an evaluation that does not include at least one visual memory measure may not
adequately identify all cases of amnestic MCI (Smith & Bondi, 2013); up to 70% of all MCI
cases eventually convert to AD at a rate of 10-15% per year (Budson & Solomon, 2011), making
visual memory an important factor in the early detection of AD pathology. Given some findings
of asymmetric patterns of atrophy in AD (Derflinger et al., 2011), and because visual memory is
presumed to be localized to the right hemisphere (Lezak, Howieson, & Loring, 2004), a
neuropsychological evaluation of memory impairment cannot be considered complete without
the inclusion of at least one measure of visual/non-verbal memory.
There is evidence to suggest that visual memory may also decline more quickly than
verbal memory with increasing age (Skilbeck & Woods, 1980; Riege & Inman, 1981). Verbal
memory, on the other hand, appears to be more resistant to decline with age (Burkhart, 2011;
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Gale, Baxter, Connor, Herring, & Comer, 2007; Sheslow & Adams, 2003). Other studies have
failed to confirm the idea of differential cognitive decline with age (Salthouse, Fristoe, & Rhee,
1996). It is also unclear to what extent verbal abilities mediate performance on visual memory
measures, although it seems likely that this varies depending on the chosen measure. Bornstein
and Chelune (1989), in a factor analysis of the WMS-R, found that the loading of non-verbal
memory on a verbal ability factor increased with age. This would suggest that older adults may
rely more heavily on verbal memory and skills (which presumably decline more slowly) than
their younger counterparts.
Performance on visual memory measures has been shown to differentiate between groups
of AD patients and normal controls. In a meta-analysis of 47 studies that included 1,207
preclinical AD and 9,097 controls, Bäckman, Jones, Berger, Laukka, and Small (2005) found an
episodic memory effect size of about 1.03; within the domain of episodic memory, the largest
effect sizes were found on delayed recall tasks. Troyer and colleagues (2008) used a modified
scoring procedure to show that, in a sample of aMCI patients and normal controls, associative
memory showed a larger between-groups difference than item memory.
Visual memory impairment can also predict conversion to AD in normal and memoryimpaired participants. In population studies, visual memory impairment can be detected up to 10
years preceding a diagnosis of AD (Kawas et al., 2003; Tierney, Yao, Kiss, & McDowell, 2005).
A population-based study conducted by Albert and colleagues (2001) measured a group of 165
participants with and without memory complaints. Participants were classified at baseline as
either cognitively normal or questionable AD. At a 3-year follow-up visit, participants were then
classified as either cognitively normal, questionable AD, or probable AD. All participants
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completed 20 neuropsychological measures (covering the domains of memory, language,
executive function, and visuospatial skills) at both time points. Using a stepwise discriminant
function analysis, the authors demonstrated that performance on one measure of visual memory
at baseline accurately differentiated participants who converted from normal to AD and from
questionable AD to AD.
In a sample of 145 normal controls and AD patients, Swainson and colleagues (2001)
found that the Paired Associates Learning task of the Cambridge Neuropsychological Test
Automated Battery (CANTAB), a visual memory measure, differentiated normal controls from
AD patients and depressed patients from AD patients, and classified certain questionable AD
patients as actually having AD. Blackwell and colleagues (2004) demonstrated, in a sample of 43
patients with questionable AD followed over 32 months, that 11 participants (26%) converted to
AD while 29 participants (67%) remained in the questionable AD group; the CANTAB Paired
Associates Learning task predicted conversion to AD with 100% accuracy. A measure of
immediate visual memory reliably differentiated slow and fast progression of cognitive decline
(Buccione et al., 2007). Eslinger, Damasio, Benton, and Van Allen (1985) compared a sample of
patients with dementia due to a variety of etiologies and found that a combined factor that
included visual retention, as well as verbal fluency and orientation to time, classified participants
as normal or demented with 89% accuracy.
Findings such as these have been extended to patients with MCI. In a sample of 166
consecutive patients referred to a memory clinic, Alladi and colleagues (2006) found that out of
124 patients who met inclusion criteria (not demented, not depressed), 72 of them (58%) were
classified as having MCI when Petersen criteria (Petersen et al., 1999) were used (which judges
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episodic memory deficits using only verbal memory measures), while 90 of them (73%) were
classified as having MCI if episodic memory impairment was documented with either verbal
memory measures or a visual memory measure (CANTAB Paired Associates Learning). Using
the DMS48, a measure of visual recognition memory, De Anna and colleagues (2014) studied a
group of 33 patients with amnestic MCI and 26 normal controls and found that impaired
recognition memory at baseline predicted greater decline in cognition after 18 months; all 3
participants who converted to AD belonged to the group that was impaired at baseline. Thorough
reviews of visual/nonverbal memory testing have been written by (1997) and Iachini, Iavarone,
Senese, Ruotolo, and Ruggiero (2009).
Comparing and Choosing Measures
Episodic memory is not a unitary construct. Theory and practice suggest that it can be
subdivided into verbal and visual/nonverbal processes. The construct of visual/nonverbal
memory can be measured in different ways, which can influence whether and how it relates to
verbal memory and episodic memory in general. The multi-store model of memory (Atkinson &
Shiffrin, 1968) proposes a processing system that encodes, retains, and retrieves incoming
perceptual information. Information is encoded, retained, and retrieved separately in conjunction
with how the information is perceived. Indeed, Phillips and Christie (1977) found that visual
memory has STM and LTM characteristics that are consistent with the Atkinson-Shiffrin
(Atkinson & Shiffrin, 1968) model.
Immediate recall measures assess the degree to which information has been properly
encoded, while delayed recall tasks measure how much information was retained and how well it
was retrieved. Assuming adequate encoding, differential performance on uncued (recall) and
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cued (recognition) delayed retrieval tasks may clarify whether impairment in retrieval is due to
impaired retention or retrieval difficulties. Even recognition tasks can be subdivided into
multiple-choice, yes-no recognition, or forced-choice (either-or) recognition to further clarify the
nature of a retrieval deficit. Information to be processed may be not only verbal or nonverbal in
nature but also simple or complex, concrete or abstract, meaningful or rote.
When comparing tests to one another, issues of validity emerge. In general, validity is
demonstrated by evidence that the test measures what it claims to measure (Gregory, 2007). Face
validity suggests that a test appears to measure what it actually does measure. For example, a
visual memory test most likely involves asking the examinee to memorize some visual
information and recall it later. A list-learning task in which words are read aloud to the examinee
is not face valid as a measure of visual memory. Another form of validity, one that is more easily
demonstrated in research, is construct validity, or evidence in support of group differences that
are consistent with an underlying theory of the construct being measured. If visual memory is
impaired in patients with right temporal lesions, and if those patients scores on visual memory
measures differ significantly from the population mean, construct validity has been
demonstrated. When multiple tests are available, each of which has adequate construct validity,
they may be compared to each other to demonstrate convergent validity, or evidence that test
scores correlate with each other when administered to the same group of people, indicating that
they all measure a similar construct in similar ways. Finally, there is ecological validity, a form
of validity that is becoming increasingly important. A test may be considered ecologically valid
if performance on the test in a clinical setting (strength or weakness) is related to real-world
functioning. For example, a visual memory measure may be considered ecologically valid if
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people who perform poorly on it also perform poorly on an informant-reported measure such as
ADLs. In terms of ecological validity, visual memory measures are relevant to some of the
problems that people with MCI and AD most frequently face, including misplacing objects
around the house or getting lost while driving.
Visuospatial tasks can also differentiate AD from Parkinson’s disease dementia or
dementia with Lewy bodies (two diseases whose underlying pathophysiology is presumed to
differ significantly from AD) and frontotemporal dementia (again, a disease with a different
underlying etiology) from AD (Jacova et al., 2007; Pachana, Boone, Miller, Cummings, &
Berman, 1996) making them a useful addition to a neuropsychological test battery when
underlying etiology is uncertain.
Existing Comparisons between Measures
Several past studies have compared visual memory measures, although none directly
compared the subtests and measures proposed for this study. A doctoral dissertation completed
by Hall (2006) compared the WRAML2 to the WMS-III in a clinical sample of diagnosed AD
patients and found that, with the exception of verbal memory and overall memory index scores,
the WRAML2 and the WMS-III were generally not equivalent. However, Hall demonstrated
differences between visual memory indexes (WRAML2 Visual Memory vs. WMS-III Visual
Immediate, d = .58, and WRAML2 Visual Recognition vs. WMS-III Visual Delayed, d = .72).
Using a Bonferroni correction for multiple comparisons, the difference between WRAML2
Visual Recognition and WMS-III Visual Delayed remained significant. Correlations were also
reported: WRAML2 Visual Memory and WMS-III Visual Immediate, r = .64; WRAML2 Visual

Running head: TESTS OF VISUAL MEMORY

15

Memory and WMS-III Visual Delayed, r = .21; WRAML2 Visual Recognition and WMS-III
Visual Immediate, r = .44; WRAML2 Visual Recognition and WMS-III Visual Delayed, r = .77.
There are several important differences between Hall’s study and the present study. Her
sample was actively recruited from the community rather than passively recruited in a clinical
setting; the sample included a disproportionate number of female participants, despite evidence
that the incidence of AD is approximately equal for males and females (Alzheimer’s Association,
2014); participants were already diagnosed with Alzheimer’s disease in the mild to moderate
stages (no MCI patients were included); some were being treated with medications, but it was
not clear which medications or at which doses; participants were included only if they scored
between 18 and 23 on the MMSE, potentially omitting those who scored between 24 and 26 who
may have had memory and functional impairment consistent with a diagnosis of AD; the WMSIII rather than the WMS-IV was used because the WMS-IV had not been published at the time;
and participants with depression were excluded, despite evidence that depression can be a
symptom of early AD rather than a confounding causal factor.
Frise (2009) found that a difficult visual memory task (the Rey-Osterrieth Complex
Figure Test; RCFT; Rey, 1941), as typically scored, had too high of a floor to measure
meaningful differences in older adults. Burkhart (2011) extended this finding to AD patients.
Neither study made comparisons between multiple visual memory measures, but both suggest
that as impairment worsens, the importance of variability in scores at the lowest levels of
performance increases, as measures that generate a broader range of age-controlled scaled scores
are more useful in making clinical decisions.
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In a study of 113 patients, Golden and colleagues (2005) compared differences between
groups of patients with vascular dementia and AD and found that the vascular dementia group
performed better overall, with “similar scores on complex tests and different scores on basic
tests” (p. 1570). Correlations between measures were not reported, and no normal controls were
studied. Cherner and colleagues (2007) collected normative data for the BVMT-R in a sample of
127 Spanish-speaking participants of Mexican descent and noted the importance of including
education as a demographic correction when using the BVMT-R in this population. Their sample
ranged in age from 18 to 79 years; the mean age was 38.6 years (SD = 18.0), and they cautioned
that their data should not be used with older Spanish-speaking adults.
Gale, Baxter, Connor, and Herring (2007) administered Form 4 of the BVMT-R to a
sample of 172 cognitively normal adults between the ages of 60 and 89. Normative data were
provided for 14 overlapping age groups, reflecting the structure of normative data provided by
the BVMT-R professional manual. In an unpublished doctoral dissertation, Gurczynski (2009)
administered Form 1 of the BVMT-R to a sample of 49 cognitively normal adults above the age
of 80. Normative data were provided for two age groups (80–84: N = 36; 85–89: N = 13). In a
doctoral dissertation that was subsequently published in a peer-reviewed journal, Kane (2012;
Kane & Yochim, 2014) administered Form 1 of the BVMT-R to a sample of 175 participants
(109 normal controls, 49 residents of independent or assisted living communities, 17 patients at
community mental health center). Scaled scores for Total Recall were significantly correlated
with age, r = -.29, p < .01, and education, r = .35, p < .01). Scaled scores for Delayed Recall
were also correlated with age, r = -.32, p < .01, and education, r = .38, p < .01. Normative data
were provided for a subset of participants in either the normal group or the assisted-living group
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who were aged 80 or older and were judged to be cognitively normal (N = 59), grouped by age
and level of education. However, data for all education levels were only provided for the 80–88year-old age group (N = 29).
An unpublished doctoral dissertation by McCoy (2004) evaluated intra-individual
variability in cognitive scores over 15 days in participants with amnestic MCI (N = 15) and
normal controls (N = 53) over the age of 65. Participants were administered the BVMT-R as part
of a comprehensive neuropsychological test battery on the first visit only. Means and standard
deviations were reported for BVMT-R Immediate raw scores and BVMT-R Delayed T scores in
each group. The mean BVMT-R Immediate raw score was approximately 9 points lower (out of
a possible 36 points) in the MCI group than in the control group, t(66) = -5.113, p < .001, d = 1.53. The mean BVMT-R Delayed T score was 16.7 points lower in the MCI group than in the
control group, t(66) = 6.546, p < .001, d = -1.88. No other visual memory measures were
compared.
Means and standard deviations for scores in these studies relevant to the present study are
presented in Table 1. With the exception of these studies, few data are available comparing these
measures to one another.
Do Visual Memory Tests Measure Visual Memory?
The literature presents conflicting views of whether visual memory tests actually measure
visual and not verbal or general memory. In other words, divergent validity between verbal and
visual memory tests is sometimes difficult to demonstrate. Perhaps because of its status as one of
the most widely used memory measures (Strauss, Sherman, & Spreen, 2006), the Wechsler
Memory Scale appears to be the measure that is most frequently subjected to factor analytic
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Table 1
Comparison of Performance on BVMT-R in Several Clinical Studies
BVMT-R Score
BVMT-R Immediate
Study
Gale et al. (2007)

Gurczynski (2009)

Kane & Yochim (2014)

BVMT-R Delayed

Age Range

N

Mean

SD

Mean

SD

80–84

41

14.8

6.0

6.5

2.8

82–86

29

14.6

6.0

6.3

2.7

84–88

16

13.1

5.0

5.4

2.7

86–89

19

14.2

5.2

6.3

2.7

80–84

36

14.72

5.90

6.03

2.47

85–89

13

12.92

5.27

5.92

3.25

80–88

29

15.52

5.40

6.41

2.01

Note. BVMT-R = Brief Visuospatial Memory Test, Revised Edition.

scrutiny. Several studies conducted by Leonberger, Nicks, and colleagues have failed to
demonstrate the existence of a visual memory factor that is separate from a general visuospatial
factor (Leonberger, Nicks, Goldfader, & Munz, 1991; Leonberger, Nicks, Larrabee, &
Goldfader, 1992; Nicks, Leonberger, Munz, & Goldfader, 1992). The same pattern was
demonstrated by Burton, Mittenberg, and Burton (1993).
In factor-analytic studies of verbal and visual memory, visual memory consistently loads
on a separate factor (Bowden, Carstairs, & Shores, 1999; Hoelzle, Nelson, & Smith, 2011;
Holdnack, Zhou, Larrabee, Millis, & Salthouse, 2011; Millis, Malina, Bowers, & Ricker, 1999;
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Price, Tulsky, Millis, & Weiss, 2002; Sewell, Downey, & Sinnett, 1988; Tulsky & Price, 2003).
On the other hand, Leonberger and colleagues (1992) found (on the WMS-R) that “separate
verbal and visual memory components failed to emerge. Moreover, several tests intended to
measure visual memory did not load on the general memory factor, loading instead with
nonverbal and spatial cognitive skills”.
Larrabee, Kane, and Schuck (1983) conducted a factor analysis comparing WMS and
WAIS subtests in a sample of 256 normal and non-normal subjects and were not able to
demonstrate evidence that the Visual Reproduction subtests load on a separate visual memory
factor. The same group later demonstrated that Visual Reproduction II did load on a visual
memory factor, while Visual Reproduction I loaded on a general visuospatial factor (Larrabee,
Kane, Schuck, & Francis, 1985) or visual/performance IQ factor (Larrabee & Curtis, 1995).
Using another visual memory measure, the Continuous Visual Memory Test (CVMT; source),
the group demonstrated additional evidence for a combined immediate visual memory/nonverbal
factor, while delayed visual memory emerged as a “pure” visual memory factor (Larrabee,
Trahan, & Curtiss, 1992).
Bornstein and Chelune (1988), in a sample of 434 normal controls, found that verbal and
visual memory loaded on separate factors only when delayed recall was included. The third
factor was related to attention and IQ; a similar factor structure (verbal memory, visual memory,
attention/concentration) was found in the WRAML2 normative study (Sheslow & Adams, 2003).
It is also unclear whether and how neurological diseases such as AD affect the
relationship between visuospatial abilities and visual memory. Deluca and Cicerone (1991)
found a combined visual ability/memory factor in a sample of 59 brain-injured patients. In a
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study of 308 normal controls, 35 AD patients, and 35 Huntington’s disease patients (who
presumably have intact medial temporal lobes), Delis, Jacobson, Bondi, Hamilton, and Salmon
(2003) found that CVLT immediate total and long delay free recall were significantly correlated
in the control group (r = .81) and in the Huntington’s disease group (r = .85) but only moderately
in the AD group (r = .36). To address the issue of restricted range, they conducted a post-hoc
analysis between the AD group another sample of Huntington’s disease patients that was chosen
to match the AD group in terms of variability in scores. California Verbal Learning Test (CVLT)
immediate total and long delay free recall were still significantly correlated in the separate
Huntington’s disease group (r = .66). They also conducted a factor analysis of CVLT scores in a
group of AD patients and found that immediate and delayed memory loaded on separate factors,
whereas immediate and delayed memory tend to load on a single factor in normative studies.
In a population study, Heilbronner, Buck, and Adams (1989) were not able to separate a
pure nonverbal memory factor from a general nonverbal factor, suggesting that visuospatial
deficits may explain more of the variability in visual memory scores than visual memory itself.
Of course, visual memory is strongly influenced by visuospatial skills (Heilbronner, 1992).
Because AD affects the parietal lobes (Querfurth & LaFerla, 2010), which are presumed to
mediate most visuospatial skills (Lezak et al., 2004), AD may lead to differentially impaired
performance on visual memory measures as compared to verbal memory measures. Regarding
the ease with which supposedly non-verbal content can be verbalized, Eadie and Shum (1995)
demonstrated that Chinese characters are more difficult to verbalize, at least for Englishspeaking participants, than geometric designs. This is unlikely to be true for readers of Chinese,
as Adams and deBros (2010) demonstrated evidence that there are some small differences in
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visual memory performance between English-speaking and Chinese-speaking children that
diminished with age.
Purposes of the Present Study
There is potential utility in alternate methods of assessing visual memory. For example,
different tests have different psychometric properties that may indicate the use of one over
another in certain clinical groups; tests with reliability values of less than .80 are generally unfit
for clinical use, and reliabilities of .90 are expected when conducting “high stakes” testing (e.g.,
forensic evaluation, intellectual assessment). There are also pragmatic concerns, in that some
tests are easier or faster than others to administer. Before using any new measure, however, the
clinician must ascertain whether a test is equivalent to other tests that have been proven over
multiple studies to be reliable and valid. This can be done informally by comparing normative
data provided by test authors, but judgments made using such information is limited by the test
authors’ choices of clinical samples as well as the fact that different measures are compared at
different times in different samples that may not be comparable. Demographic data change over
time, limiting the generalizability of the results of normative studies (Flynn, 1987). Memory tests
are updated on varying schedules; because of changes in administration and scoring procedures,
it is necessary to demonstrate the relationships between the most recent editions of each test in
order to compare them before deciding which to use for which purposes. Given so many
potentially distinct memory processes and systems and even more methods by which to assess
their strengths and weaknesses, practicing clinicians are left to decide on their own how to go
about choosing “the best tool for the job.” For clinical purposes, then, equality is best judged by
a head-to-head comparison of multiple measures in the same clinical sample.
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Rationale
The present study was not intended to address construct validity from a factor-analytic
standpoint, but rather to clarify some important questions in order to aid clinical decisionmaking. In a review of visual memory measures, Moye (1997) concluded that future studies
should address several key issues:
Research should incorporate new and potentially superior design memory tests …
Construct validity research should incorporate item analyses to study aspects of test
stimuli that may relate to test specificity and overall reliability … Construct validity
research could examine the relationship of performance on different nonverbal memory
tasks with one another, with areas of brain function, and in predicting everyday function
… Studies that collect and compare multiple paradigms and multiple tests for each
paradigm may facilitate our understanding of the more general content domain for the
construct of nonverbal memory, and the extent to which various paradigms estimate this
domain (p. 167).
The present study aimed to address items 1 and 3 from Moye’s (1997) list.
When working with AD and MCI patients, clinicians must measure multiple cognitive
domains in a relatively short amount of time, ideally in one test session, with patients who are
easily fatigued and are likely to be cognitively impaired. Because of the importance of early
detection (Alzheimer’s Association, 2014), the most sensitive measures of cognitive decline
must be determined while awaiting additional evidence that biomarkers, such as PET using
amyloid-binding radioactive markers and cerebrospinal fluid (CSF) amyloid tests, become as
reliable as cognitive tests in detecting the disease (Budson & Solomon, 2011).
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The diagnostic test battery used at The Memory Clinic consists of selected subtests that
were chosen for their sensitivity and specificity and have remained relatively unchanged (aside
from the addition of new versions of the same subtests) for the past 25 years. One of the
measures used in this study (WMS-IV Visual Reproduction; Wechsler, 2009) was part of that
battery until approximately two years ago, when it was arbitrarily replaced with the Brief
Visuospatial Memory Test, Revised Edition (BVMT-R; Benedict, 1997). Although the Visual
Reproduction subtest has decent psychometric properties, it requires a significant amount of time
and effort to administer and score, and observations suggest that patients find it difficult and
unpleasant to complete; scores derived from the measure, at least in the population of patients
seen at the clinic, tend to fall into a bimodal distribution, limiting conclusions that can be made
to binary yes-no decisions about impairment. The decision to replace it with the BVMT-R was
made on practical grounds: it is particularly easy to administer and score; it is brief; it provides
information about learning over multiple trials as well as delayed recall and recognition tasks;
and it is less daunting to patients, at least according to the observations of examiners.
If the measures are determined to be equivalent in terms of psychometric properties, the
choice can be made on pragmatic rather than statistical grounds. Otherwise, if significant
differences were found between measures, empirical decisions could be made in order to
maximize the effectiveness of the overall test battery. Because there are many more visual
memory measures available for purchase, we decided to compare the WMS-IV and the BVMT-R
to two additional measures from the Wide Range Assessment of Memory and Learning, Second
Edition (WRAML2), Design Memory and Picture Memory. Each of these measures was
demonstrated in normative studies to be clinically useful in differentiating AD patients from
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normal controls (Benedict, 1997; Sheslow & Adams, 2003; Wechsler, 2009). It was therefore
judged to be acceptable to choose one or another of these measures for use in the battery.
When the WMS-IV Visual Reproduction subtest was replaced with the BVMT-R in The
Memory Clinic’s test battery, little empirical evidence was available comparing the two
measures. A head-to-head comparison using the same sample of patients was judged to be the
best way to gather data allowing the choice of one over another. The present study was
conducted to address some of the limitations of previous comparative studies and to provide
additional data that did not yet exist for these particular visual memory measures. A sample of
new patients referred to The Memory Clinic due to subjective memory complaints were
evaluated using all of the above-mentioned visual memory measures; those who went on to
receive a diagnosis of AD or MCI due to AD pathology based on the results of the evaluation
were included in the clinical group. The measures were also administered to a convenience
sample of normal controls in order to compare the measures to each other in a non-impaired
group and to compare performance on measures between groups. The latest editions of each
measure were used in order to provide results that may be useful to the practicing clinician.
Hypotheses
1. Based on normative data (Benedict, 1997; Sheslow & Adams, 2003; Wechsler, 2009), it
was hypothesized that measures would be moderately to strongly correlated with each
other in this sample. Theoretically, if visual memory is a unitary construct, different
methods of measuring the construct should yield similar results in the same group of
patients.
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2. It was hypothesized that the strength of the relationships between visual memory
measures within each subgroup would not differ significantly between subgroups.
3. It was hypothesized that the mean scores for each visual memory measure would differ
between subgroups. As originally stated, this meant that each mean score for each
individual visual memory measure would differ between subgroups.
4. It was hypothesized that differences between mean scaled scores for each measure would
differ between groups. In other words, measures may be equivalent in the overall sample
but not in either subgroup, or else in one subgroup but not in the other. Specifically, it
was hypothesized that, while the control group would perform relatively well on most
measures, larger differences in performance between measures would be found in the
clinical group.
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Chapter 2
Method
Participants
The present study used a cross-sectional design to compare two groups of participants
who were presumably normal and memory impaired. Participants were selected from the
population of clinician-referred patients at a memory disorders clinic in Bennington, Vermont.
All new patients who presented for evaluation were offered an opportunity to participate in the
study. The control group was selected from a population of caregivers of current patients and
community-dwelling older adult volunteers who did not have subjective memory complaints
when they were approached to solicit participation. The initial proposal called for caregivers of
new patients (typically a spouse, child, or sibling) to participate as controls. Upon further
consideration, however, some additional concerns emerged regarding that strategy. In particular,
concerns were voiced by the staff of the Memory Clinic that this may place an undue burden on
the families of patients who were in the process of undergoing evaluation and who would most
likely receive a diagnosis of intractable neurological decline. A decision was made to approach
the caregivers and relatives of patients who were already enrolled in clinical trials and who
visited the clinic regularly. These caregivers were known to be interested in contributing to
scientific knowledge, and the already-established relationship with them made it easier to request
assistance for the present study. In addition, the parents of some staff members, most of whom
were not caregivers of AD patients but who were in the desired age range and did not have
subjective memory complaints, were also recruited for the control group.

Running head: TESTS OF VISUAL MEMORY

27

Inclusion/exclusion criteria and rationale for combined MCI/AD sample. The AD
research community is moving toward a consensus that amnestic MCI represents an intermediate
or preclinical stage of AD pathophysiology (Albert et al., 2011; Morris et al., 2001). The
underlying biological changes that precede AD begin long before cognitive symptoms are first
observed (Budson & Solomon, 2011). MCI is a clinical diagnostic entity that represents a point
on a continuum of cognitive changes at which impairment is present but not severe enough to
produce functional deficits (Petersen et al., 1999). Patients who present for memory evaluation
may lie anywhere along the continuum; the stage of pathology is not typically known at the time
of evaluation. Therefore, analyses conducted on samples that include both MCI and AD patients
should provide data that are useful to clinicians who may expect to see patients at varying stages
of pathology. Accordingly, participants were included in the clinical sample if their initial
evaluation resulted a diagnosis of either possible/probable Alzheimer’s disease or MCI single- or
multiple-domain amnestic type (i.e., MCI due to Alzheimer’s disease pathology), in the absence
of other forms of dementia. The risk of developing Alzheimer’s disease increases with age, from
2.5% at age 65 to almost 50% at age 85 (Budson & Solomon, 2011), although most cases of AD
are diagnosed after the age of 65 (Alzheimer’s Association, 2014). On the other hand, the risk of
developing MCI is not as closely tied to age. Therefore, participants of any age were screened for
inclusion in the study.
Patients who present with subjective memory complaints have not usually been
diagnosed and are almost never receiving treatment for AD. However, some new patients request
an evaluation to confirm or clarify a diagnosis made by a primary care physician or a neurologist
who may not have access to neuropsychological test results. In such cases, the patient may have
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been prescribed symptomatic medication such as an acetylcholinesterase inhibitor by the
referring physician. Symptomatic medications are known to have a positive effect on cognition
in general (e.g., MMSE scores; Rogers et al., 1998). Therefore, participants who were already
taking one or more medications approved by the FDA for the treatment of Alzheimer’s disease
(including off-label) at the time of their initial evaluation were excluded from the sample.
Participants were also excluded if they reported taking over-the-counter cholinergic medication,
such as Huperzine A (Wang et al., 2009).
There are many FDA-approved medications (e.g., opioids, benzodiazepines,
antipsychotics, antiepileptics, antihistamines, etc.) that may interfere with memory (Budson &
Solomon, 2011), particularly those that have strong anticholinergic effects, such as tricyclic
antidepressants and certain mood stabilizers (Julien, 2007). Given the likelihood that about 90%
of older Americans have taken at least one prescription medication in the past month (Gu,
Dillon, & Burt, 2010), the likelihood that one or more of those medications may have some
effect on cognition is high (Obermann, Morris, & Roe, 2013). However, because the results of
this study were intended to be generalized to a population whose medication history is unknown
at the time of testing, participants taking one or more FDA-approved medications were excluded
from the analysis only if the evaluation resulted in a recommendation that a medication be
discontinued due to its adverse cognitive effects.
A variety of neurodegenerative disorders fall under the umbrella term dementia, but there
is heterogeneity in the presentation and symptoms depending on presumed etiology. Therefore,
participants diagnosed with other neurocognitive disorders (including but not limited to vascular
dementia, mixed dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinson’s
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disease, corticobasal degeneration, progressive supranuclear palsy, normal pressure
hydrocephalus, Wernicke-Korsakoff syndrome, or variant Creutzfeldt-Jakob disease) were
excluded. In order to minimize the influence that the residual cognitive symptoms of a brain
injury may have on test performance, participants were excluded if they (or knowledgeable
informants such as a caregivers or close relatives) reported a history of traumatic brain injury
with loss of consciousness greater than 5 seconds within 5 years of the time memory symptoms
were first noticed. Participants with a documented metabolic disorder, such as hypothyroidism or
vitamin B12 deficiency, were excluded, as such deficiencies can mimic dementias and/or
exacerbate cognitive symptoms. Finally, because people with Down syndrome almost invariably
develop AD pathology (Budson & Solomon, 2011), one patient with Down syndrome was
excluded from the sample.
Depressive symptoms can cause or exacerbate cognitive symptoms, and the distinction
between the two is not always clear. The onset of later-life depression often co-occurs with the
onset of cognitive symptoms, and apathy is often a behavioral symptom of AD (Budson &
Solomon, 2011). Therefore, patients who are being treated for depression will be included unless
it is clear, as judged by the diagnostic team in reviewing the results of a depression screening
measure (Geriatric Depression Scale) and diagnostic interview, that major depressive disorder is
the primary cause of the participant’s reported cognitive symptoms, in the absence of a diagnosis
of AD or MCI.
Demographic characteristics. The overall sample consisted of 40 participants, of which
18 (45%) were male and 22 (55%) were female. Age ranged from 58-90, level of education
ranged from 8-20, and estimated premorbid intellectual ability (WTAR Estimated IQ) ranged
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from 82-119. Table 2 lists means and standard deviations for demographic variables in each
group.

Table 2
Demographic Characteristics by Group
Clinical Group

Control Group

Mean

Variable

Mean

SD n

Mean SD n

Difference

Age

79.4

7.5 20

73.3 6.9 20

6.1

.011 .85

Years of Education

14.6

3.2 20

16.9 2.8 20

-2.3

.018 -.76

104.6 12.8 20

113.3 5.9 20

-8.7

.010 -.87

p

d

Estimated Premorbid IQ
(WTAR)

Note. WTAR = Wechsler Test of Adult Reading.

Clinical group. Out of 79 patients who presented for clinical evaluation, 28 were
excluded (5 previous head injury, 5 ongoing medical condition, 5 psychiatric, 4 prior stroke, 4
presenting problem not related to memory, 2 previously diagnosed, 1 Down syndrome, 1 blind, 1
deaf). Of the remaining 51 patients who were offered an opportunity to participate, 11 declined,
leaving 24 participants in the preliminary clinical group. After all participants in the clinical
group completed the research battery, 4 participants were excluded from analyses due to
receiving a diagnosis that was not AD or MCI (depression/anxiety = 3, mixed dementia = 1). The
final clinical group was comprised of 20 participants, of which 14 were diagnosed with AD and
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6 with MCI. Of those 20 participants, 8 were male (40%) and 12 were female (60%). Age ranged
from 69-90, level of education ranged from 8-20, and estimated premorbid IQ ranged from 82119. Table 2 lists means and standard deviations for demographic variables in the clinical group.
In the clinical group, the mean MMSE score was 21.9 (SD = 4.6), with a range of 13-27. The
mean MoCA score was 17.2 (SD = 4.8), with a range of 9-24. The mean ADAS-Cog score was
15.9 (SD = 8.5), with a range of 5-35. The mean ADL score was 24.1% (SD = 22.9%), with a
range of 1%-69%. All patients lived in private residences, either independently or with an unpaid
caregiver (typically a spouse, son, or daughter).
Control group. All potential control group participants consented to participate in the
study. The control group consisted of 20 participants, of whom 10 were male (50%) and 10 were
female (50%). Table 2 lists means and standard deviations for demographic variables in the
control group. Of note, the level of education of the control group differed dramatically from
population estimates derived from U.S. Census data from 2010. Of Americans over the age of
60, 34.78% held at least a high school diploma, 13.47% held at least a bachelor’s degree, 5.40%
held at least a master’s degree, and 1.02% held at least a doctorate or professional degree. In the
control group, all participants (100%) held at least a high school diploma, 15 participants (75%)
held at least a bachelor’s degree, 11 participants (55%) held at least a master’s degree, and 5
participants (25%) held at least a doctorate. A review conducted by Sinnett and Holen (1999)
found that WMS-R VR I is sensitive to age and VRII is sensitive to age, SES, and age × SES
interaction.
Comparisons between groups. Independent-samples t-tests were carried out to
determine whether there were meaningful differences in demographic characteristics between the
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clinical and control groups. The mean age of the clinical group was significantly greater than the
mean age of the control group (t(38) = -2.66, p = .011, d = -.85). The mean level of education of
the clinical group was significantly smaller than the mean level of education of the control group
(t(38) = 2.47, p = .018, d = .77). The mean estimated premorbid IQ of the clinical group was
significantly less than the mean estimated premorbid IQ of the control group, t(38) = 2.763, p =
.010, d = -.87. A chi-square test did not reveal a significant difference in gender between groups
(χ2 = .404, p = .751). Differences between groups are summarized in Table 2 above.
In the overall sample, age, education, and estimated premorbid IQ were all significantly
correlated with each other. Age was moderately negatively correlated to level of education (r = .418, p = .007), and to estimated premorbid IQ (r = -.331, p = .037). Level of education was
strongly positively correlated to estimated premorbid IQ (r = .560, p < .001). Within each group,
some correlations between demographic variables were significant (Table 3).

Table 3
Correlations Between Demographic Variables by Group

Subtest

Age

Age
Education

-.276

Estimated Premorbid IQ

-.090

Years of

Estimated

Education

Premorbid IQ

-.369

-.498
.557

.479

Note. Unshaded = clinical group, shaded = control group; bold text indicates
significance at or below the p = .05 level; WTAR = Wechsler Test of Adult
Reading.
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Measures
The three measures were chosen for their ease of use, their uniqueness, and the short
amount of time required to administer. For the WMS-IV and the BVMT-R, participants were
told to expect a delayed recall condition. They did not expect a delayed recognition condition for
WRAML2 subtests.
Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2). The
Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2; Sheslow & Adams,
2003) is an individually-administered, standardized battery of memory tests for use in children
and adults ages 6 to 89. The Design Memory and Picture Memory subtests, along with their
recognition components, were used in this study. The Design Memory subtest consists of 5 cards
with increasingly complex abstract designs. For each card, the participant is allowed 5 seconds to
study the designs before the card is removed from view. After a 10-second delay, the participant
is asked to draw the designs from memory with as much detail as possible on a response form.
There are 12 possible correct responses for each card; raw scores for the entire subtest range
from 0-60. The Picture Memory subtest consists of 4 full-color drawings of common scenes
(e.g., a family at a zoo, some friends watching television). For each card, the participant is
allowed 10 seconds to study the drawing before the card is removed from view. Another drawing
is then presented that is similar to the original with certain key components moved, changed, or
added. For each repetition, the participant must place an ‘X’ on any of the 8 parts of each scene
that has been moved, changed, or added. Raw scores for the entire subtest range from 0-32.
Design Memory Recognition is a yes-no recognition task consisting of 46 designs, 23 of which
were present on the original cards. Picture Memory recognition is a yes-no recognition task
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consisting of 44 smaller sections of the original 4 drawings or the 4 modified drawings, some of
which were present and some of which are new. Both are administered approximately 20
minutes after the completion of the respective immediate recall subtests. For each recognition
subtest, the participant must indicate whether a particular part of the design or drawing was seen
during the immediate recall subtest; there are 46 items on the Design Memory Recognition
subtest and 44 items on the Picture Memory Recognition subtest. Raw scores for the Design
Memory Recognition subtest range from 0-46; however, scores of less than 23 are highly
unlikely, as a response of “No” on every item (the participant does not recall any of the true or
sham items) would yield a score of 23. Raw scores for the Picture Memory Recognition subtest
range from 0-44; scores of less than 22 are highly unlikely, as a response of “No” on every item
(the participant does not recall any of the true or sham items) would yield a score of 22. For both
recognition subtests, random guessing should yield a score of at least 50% correct.
The WRAML2 demonstrated adequate reliability and validity in normative studies.
Coefficient alphas for the subtests and age groups used in this study are shown in Table X below.
Inter-rater reliability using the rubrics provided to score the Design Memory subtest ranged from
.976 to .981 (Sheslow & Adams, 2003). In clinical samples, both Design Memory and Picture
Memory demonstrated utility in distinguishing AD patients from matched controls (Table 4).
Wechsler Memory Scale, 4th Edition (WMS-IV). The Wechsler Memory Scale, 4th
Edition (WMS-IV; Wechsler, 2009) is an individually-administered, standardized battery of
memory tests. Only the Visual Reproduction subtests, including Visual Reproduction
Recognition, were used in the study. This subtest consists of 5 cards on which increasingly
complex geometric designs are printed. There are 2 designs on each of the final two cards. Each
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Table 4
Scaled Score Differences between AD Clinical Sample and Matched Controls on Selected
WRAML2 Subtests

Subtest/Index

AD

Controls

Mean

Mean SD N

Mean SD N

Difference

p

r

Design Memory

6.9

3.6 17

10.1

3.5 17

-3.1

.015 0.89

Picture Memory

6.1

3.4 16

8.9

3.1 17

-2.8

.020 0.85

9.1

4.0 17

11.2

2.9 17

-2.1

.086 .61

7.9

3.7 17

9.1

2.5 17

-1.1

.315 .35

Design Memory
Recognition
Picture Memory
Recognition

Note. AD = Alzheimer’s disease; WRAML2 = Wide Range Assessment of Memory and
Learning, 2nd Edition. Source: Sheslow & Adams (2003).

card is presented individually. The participant is allowed 10 seconds to study the card before it is
removed from view. The participant must then draw the design(s) as accurately as possible on a
blank response form. Responses are scored according to criteria provided in the test manual.
After a delay of 20-30 minutes, the participant is given a blank response form and asked to
reproduce the design (or designs) seen on any 1 of the 5 cards that were presented earlier. Once
the participant is satisfied with the reproduction, another blank response form is presented and
the participant is asked to reproduce another of the 5 cards. Three more blank response forms are
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presented one at a time until all cards have been attempted or until the participant is unable to
recall any more of the designs. Raw scores on each task (immediate and delayed recall) range
from 0-43. Following the delayed recall task, there is a multiple-choice recognition task. The
participant is presented with 7 cards, one at a time. Each card has 6 designs on it, 5 of which look
similar to a design that was presented earlier and one of which is exactly the same. The
participant is asked to identify which of the 6 designs is the one that was presented earlier. Raw
scores on this task range from 0-7.
The WMS-IV demonstrated adequate reliability and validity in normative studies.
Coefficient alphas ranged from .92 to .94 for Visual Reproduction I (VR I) and from .95 to .97
for Visual Reproduction II (VR II) in the 65- to 90-year-old age group. WMS-IV Visual
Reproduction demonstrated utility in distinguishing between AD/MCI and normal controls
(Table X). In the AD clinical sample, reliability coefficients were .96 for VR I and .99 for VR II.
In the MCI clinical sample, reliability coefficients were .93 for VR I and .97 for VR II. WMS-IV
Visual Reproduction demonstrated utility in distinguishing between AD/MCI and normal
controls (Table 5).
Brief Visuospatial Memory Test, Revised Edition (BVMT-R). The Brief Visuospatial
Memory Test, Revised (BVMT-R; Benedict, 1997) is an individually administered, standardized
test of visual memory and learning. It was developed as a non-verbal companion to the Hopkins
Visual Learning Test (HVLT; Benedict & Groninger, 1995). The examinee is shown a lettersized (8.5 × 11 inch) card on which six simple designs are printed in a 2 × 3 arrangement. The
examinee is allowed look at the card for 10 seconds, after which the card is removed from view
and the participant is asked to draw as many of the designs as he or she can remember, in the
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Table 5
Scaled Score Differences between AD Clinical Sample and Matched Controls on Selected WMSIV Subtests
Normal
Clinical Group
Subtest

Controls

Mean

SD

Mean

SD

N

Mean Difference

p

VR I

8.7

3.0

10.7

2.6

50

1.92

< .01

VR II

8.0

3.9

10.1

2.7

49

2.12

< .01

VR I

5.6

3.4

10.8

2.6

48

5.19

< .01

VR II

4.2

3.1

10.1

3.1

48

5.96

< .01

MCI

AD

Note. MCI = mild cognitive impairment, AD = Alzheimer’s disease, WMS-IV = Wechsler
Memory Scale, 4th Edition, VR I = Visual Reproduction I, VR II = Visual Reproduction II.
Source: Wechsler (2009).

same location on the page. The process is repeated with the same stimulus card for two more
trials. The BVMT-R is not as widely used as some of the other measures available (e.g., the
WMS-IV and the WRAML2), but it generates some additional scores that are not available when
using other measures. There are three learning trials, a 25-minute delayed recall trial, and a
delayed recognition trial that is administered immediately after the delayed recall trial. In
addition to those five trials, scores are generated for Learning (Trial 2 or Trial 3, whichever is
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greater, minus Trial 1), Total (sum of Trials 1-3), Percent Retained (delayed recall divided by the
greater score of Trial 2 or Trial 3), Recognition Hits (number of true positives) and Recognition
False Alarms (number of false positives), Discrimination Index (Recognition Hits minus
Recognition False Alarms), and Response Bias, a derived score that represents a bias toward
positive or negative responses during the recognition trial (scores range from 0 to 1, with higher
scores suggesting a bias toward “yes” responses that leads to a high number of false positives).
An advantage of the BVMT-R, particularly when assessing decline over 3- or 6-month intervals,
is the availability of six alternate forms. The authors of the BVMT-R claim that Form 2 shows
the strongest test-retest reliability characteristics, and this is the form that was used in the study.
In normative studies, BVMT-R scores were strongly correlated with other visual memory
measures, including the Wechsler Memory Scale, Revised Edition (WMS-R) and the ReyOsterrieth Complex Figure Test (RCFT), suggesting adequate convergent and divergent validity
(Table 6). In clinical samples, the BVMT-R demonstrated utility in distinguishing between
AD/mixed dementia groups and normal controls, suggesting adequate discriminative validity
(Table 7).
When working with AD and MCI patients, clinicians must measure multiple domains in a
short amount of time, ideally in one test session, with patients who are easily fatigued and are
likely to be cognitively impaired. The battery used at The Memory Clinic consists of selected
subtests and has remained relatively unchanged (aside from the addition of new versions of the
same subtests) for 25 years. One of the proposed measure (Visual Reproduction from the WMSIV) is part of that battery. The other three (WRAML2 Design Memory and Picture Memory, and
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Table 6
Correlations between BVMT-R Scores and Scores on Similar Visual Memory Measures
Measure

CFT-C

CFT-R

VR I

VR II

Immediate Recall Total

.66

.78

.66

--

Delayed Recall

.65

.78

--

.80

Discrimination Index

.33

.52

--

.50

Recognition Response Bias

-.08

.00

--

.09

Note. BVMT-R = Brief Visuospatial Memory Test, Revised Edition; CFT-C = Copy trial of the
Rey-Osterrieth Complex Figure Test; CFT-R = Recall trial of the Rey-Osterrieth Complex
Figure Test; VR I = Visual Reproduction I subtest of the Wechsler Memory Scale, Revised
Edition (WMS-R); VR II = Visual Reproduction II subtest of the WMS-R.
Source: Benedict, Schretlen, Groninger, & Dobraski (1996).

the BVMT-R) were chosen for their ease of use, their uniqueness in terms of item content and
administration procedures, and the short amount of time required to administer and score them.
The BVMT-R is unique among measures used in this study because of the use of multiple
trials to assess learning with repetition. This is important; for example, Greene, Baddeley, and
Hodges (1996) administered the doors and people test, a test of visual and verbal recall and
recognition, to a sample of 33 AD patients and 30 matched normal controls. They found that the
AD group performed worse than the control group on the doors and people test as well as on a
verbal memory measure. Performance of the AD group on the doors and people test indicated
that impaired learning (i.e., encoding difficulty) was a hallmark of the AD group. While there
was a difference between groups in the rate of forgetting verbal material, this difference was not
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Table 7
Mean Differences Between AD and Mixed Dementia Clinical Samples and Normal Controls for
Selected BVMT-R Scores
Normal
BVMT-R Score Controls

Alzheimer’s
Dementia

Vascular or Mixed Dementia

F or χ2

p

Immediate
Recall (Total)
M

19.8

6.2

6.4

SD

6.2

3.5

2.9

M

7.6

1.5

2.0

SD

2.7

1.5

1.3

M

5.7

4.8

4.5

SD

0.6

1.3

1.5

M

0.1

1.6

1.1

SD

0.4

1.5

1.3

132.3 < .0001

Delayed Recall
133.9 < .0001

Recognition
Hits
23.3 < .0001

Recognition
False Alarms
44.7 < .0001

Note. BVMT-R = Brief Visuospatial Memory Test, Revised Edition. Source: Benedict (1997).

observed for visual material. Results suggest that a multiple-trial visual memory measure make
important contributions to the assessment of episodic memory impairment in AD that are not
provided by single-trial measures. Table 8 describes the various measures used in this study in
terms of time, item content, and methodology.
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Table 8
Comparison of Time Points, Item Content, and Retrieval Paradigm between Visual Memory
Measures Used in the Present Study
Subtest

Time Point

Item Content

Retrieval Paradigm

WRAML2 Design Memory

Immediate

Geometric designs

Recall

WRAML2 Picture Memory

Immediate

Visual scenes

Recognition

WMS-IV Visual Reproduction I

Immediate

Geometric designs

Recall

Geometric designs in
BVMT-R Immediate Recall

Immediate

WRAML2 Design Memory
Recognition

Delayed

specific locations

Recall

Parts of geometric

Yes-No

designs

Recognition

WRAML2 Picture Memory

Yes-No

Recognition

Delayed

Parts of visual scenes

Recognition

WMS-IV Visual Reproduction II

Delayed

Geometric designs

Recall

Geometric designs in
BVMT-R Delayed Recall

BVMT-R Recognition

Delayed

Delayed

specific locations

Recall

Individual geometric

Yes-No

designs

Recognition

Note. WRAML2 = Wide Range Assessment of Memory and Learning, 2nd Edition; WMS-IV =
Wechsler Memory Scale, 4th Edition; BVMT-R = Brief Visuospatial Memory Test, Revised
Edition.

Procedure
Study procedures were reviewed and approved by the George Fox University Human
Subjects Research Committee before data collection commenced. As part of The Memory
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Clinic’s routine policies, each participant and/or a legally-authorized representative (LAR)
signed a form consenting to the requirements of the Health Insurance Portability and
Accountability Act of 1996 (HIPAA). Each participant and/or the LAR then signed a form
consenting to participate in the study (Appendix D).
Study measures were administered as part of the new-patient intake evaluation. Briefly,
the diagnostic process used at The Memory Clinic proceeds as follows. On the first visit, the
patient meets with a psychometrist (either a doctoral intern or a post-doctoral fellow) to complete
the neuropsychological test battery. This takes approximately 1.5 to 2 hours. In the meantime, a
doctoral-level psychologist reviews the patient’s history with caregivers and/or other reliable
informants using a semi-structured interview format. When testing is completed, a phlebotomist
draws blood from the patient for off-site laboratory analysis. The patient and his/her family then
reconvene with the psychometrist and the psychologist to complete the interview with the patient
and to discuss next steps. A follow-up visit is scheduled for 3-4 weeks later. Between the first
and second visit, the patient may undergo magnetic resonance imaging (or X-ray computed
tomography if indicated, e.g., for patients with pacemakers). If the case is diagnostically
complex, an appointment with a neurologist may be scheduled. At the follow-up visit (or after
the neurology visit), the patient is seen by a geriatrician who reviews medical history, laboratory
and imaging findings and completes a brief physical and neurological examination (if this was
not done by the neurologist). A summary of the medical evaluation is provided to the
psychologist, who then meets with the patient and caregivers and reviews the results of the
evaluation, explains the diagnostic picture, and discusses treatment options. Patients are typically
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scheduled for follow up in 3-6 months in order to document and track any changes in cognition
and function over time.
With the addition of the visual memory measures, each new patient test battery took
between 2 and 2.5 hours to complete. Each test battery was completed in a single visit without
interruption. All study measures were administered in a clean, well-lit facility, in accordance
with standard administration procedures delineated in the administration manuals. All measures
were administered by examiners who were already trained in standardized test administration
and adhered to the American Psychological Association’s Ethical Principles of Psychologists and
Code of Conduct (2002). The examiners were doctoral interns with Master’s degrees in clinical
psychology who were enrolled in APA-accredited doctoral programs in clinical psychology.
Examiners were supervised by two doctoral-level clinical neuropsychologists. Participants were
provided with opportunities to take breaks at any time in order to minimize fatigue; when breaks
were anticipated to interfere with delayed recall time limits, they were postponed until after the
delayed recall measure was completed.
In order to minimize order-of-administration effects without rearranging the entire new
patient test battery, only the visual memory measures were counterbalanced within the battery. In
this way, each participant completed non-visual memory measures in the same order, with one or
another visual memory measure inserted at one of 3 points in the sequence. Each participant may
completed the three visual memory measures within the new patient test battery in one of 6
possible orders.
Patients who present for memory evaluation sometimes become confused as the number
of tests increases and as fatigue increases. When asked to recall information after a delay during

Running head: TESTS OF VISUAL MEMORY

44

which several other distracting activities may have taken place, some patients may lose track of
what they are being asked to recall. In order to minimize this type of confusion, modifications
were made to the stimulus cards and response forms for each measure (with the exception of
WRAML2 Picture Memory). Stimulus cards and response forms for each measure were
photocopied and re-printed on paper of different colors, allowing a specific measure color to be
identified later by color (e.g., “Please draw what you saw on the green cards that I showed you a
few minutes ago.”) This minor deviation from standard procedures was not expected to have any
influence on the validity of results. Observational evidence indicated that, for those participants
who became confused about what material they were being asked to recall, the color-coding
strategy did not provide much assistance, and may not have been necessary.
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Chapter 3
Results

All statistical procedures, with the exception of ROC curve analyses, were completed
using Statistical Package for the Social Sciences (SPSS) software. Subtest raw scores were
converted to scaled scores (M = 10, SD = 3) using normative data provided in the respective
tests’ administration manuals, with the exception of the BVMT-R. Normative data for the
BVMT-R are provided as T scores (M = 50, SD = 10), which were converted to z scores (M = 0,
SD = 1) using the formula z = (T – 50) / 10 and then to scaled scores using the formula SS = 3z +
10. However, BVMT-R normative data are only provided up to and including age 79. Therefore,
BVMT-R raw scores for participants aged 80 or older were converted to z scores using means
and standard deviations provided by Gale and colleagues (2007) and from z scores to standard
scores using the formula SS = 3z + 10.
Comparison of Groups’ Performance to Each Other and to Normative Data
In order to identify similarities and differences between the participants in the present
study and participants in normative studies, thereby allowing conclusions to be made about
generalizability of the data, mean scaled scores and correlations between measures were
compared to normative data provided in the respective test manuals. One-sample t-tests were
performed using a population mean of 10, using a Bonferroni correction for multiple
comparisons to minimize Type I error. In the control group, mean scaled scores on several
measures (specifically, the WRAML2 recognition tasks and the immediate recall tasks of the
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WMS-IV and the BVMT-R) were greater than the population mean scaled score of 10. Clinical
and control group means, SDs and significance levels comparisons between the groups are found
in Table 9. The mean scaled score was lower for the clinical group than for the control group on
every measure. Comparisons between the control group and the population means (and SDs) are
found in Table 10. In the clinical group, all means were significantly lower than the population
mean scaled score of 10, with the exception of WRAML2 Picture Memory Recognition, which
approached but did not reach significance (p = 0.055). Comparisons between the clinical group
and the population means (and SDs) are found in Table 11. In the clinical group, mean scaled
scores for every measure except WRAML2 Picture Memory Recognition were significantly
lower than the population mean scaled score of 10.
For comparison purposes, the inter-correlations between measures for each group and the
respective standardization samples are found in Tables 12 and 13. As can be seen in Table 12,
correlations for the control group ranged from -.18 to .68, compared to the standardization
samples, whose correlations ranged from .26 to .78. The average correlation of the control group
was .259 (SD = .359), and for the standardization group it was .474 (SD = .197). Correlations
were compared using a Fisher transformation to convert correlation coefficients into standard z
scores. Computed z scores were then compared to each other using the formula [ z1 - z2 / sqrt ( s1
+ s2 ) ], which divides the difference between means by the pooled variance of the two groups.
Table 12 demonstrates that differences emerged between some measures but not others.
Specifically, the correlation between Picture Memory and Picture Memory Recognition, and
between Visual Reproduction I and Visual reproduction II were lower in the control group than
those reported in the measures’ respective manuals. Similarly, as can be seen in Table 13,
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Table 9
Mean Scaled Score Differences Between Clinical Group and Control Group
Clinical Group
Subtest/Index

Control Group

Mean

SD

Mean

SD

Mean Difference

p

d

Design Memory

5.7

2.2

10.2

2.7

-4.5

< .001 -1.83

Picture Memory

8.0

2.6

11.1

2.3

-3.1

< .001 -1.26

8.2

2.6

11.5

2.6

-3.3

< .001 -1.27

8.7

2.8

11.5

1.5

-2.8

< .001

5.6

3.6

12.1

3.8

-6.5

< .001 -1.76

Reproduction II

3.8

2.1

10.2

2.5

-6.4

< .001 -2.77

BVMT-R Immediate

4.9

3.6

12.0

3.5

-7.1

< .001 -2.00

BVMT-R Delayed

4.0

2.5

11.2

4.4

-7.2

< .001

Design Memory
Recognition
Picture Memory
Recognition

--

WMS-IV Visual
Reproduction I
WMS-IV Visual

--

Note. Bold text represents correlation coefficients that are significant at or below the p = .05
level. WRAML2 = Wide Range Assessment of Memory and Learning, 2nd Edition; WMS-IV =
Wechsler Memory Scale, 4th Edition; BVMT-R = Brief Visuospatial Memory Test, Revised
Edition.

correlations for the clinical group ranged from -.17 to .52. The average correlation of the clinical
group was .137 (SD = .209). Four of the 9 correlations differed significantly between the control
group and standardization samples, while only 3 differed significantly between the clinical group
and standardization samples. The correlations between VR I and VR II and between VR II and
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Table 10
Mean Differences between Control Group and Population Mean of 10 on Selected Visual
Memory Measures
Measure

Mean

SD

N

Mean

t

p

d

Difference
DM

10.20

2.71

20

0.20

0.330

.745

.07

PM

11.05

2.31

20

1.05

2.037

.056

.37

DM Recognition

11.45

2.56

20

1.45

2.529

.020

.52

PM Recognition

11.45

1.50

20

1.45

4.313

< .001

.61

VR I

12.05

3.85

20

2.05

2.384

.028

.59

VR II

10.15

2.46

20

0.15

0.273

.788

.05

Immediate

12.00

3.48

20

2.00

2.568

.019

.62

BVMT-R Delayed

11.23

4.37

20

1.23

1.254

.225

.33

BVMT-R

Note. DM = Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2)
Design Memory; PM = WRAML2 Picture Memory; VR I = Wechsler Memory Scale, 4th
Edition (WMS-IV) Visual Reproduction I; VR II = WMS-IV Visual Reproduction II. Bold text
represents p levels that are significant at or below the .05 level; bold and italic text represents p
levels that are significant at or below the Bonferroni-corrected level of p = .006.

BVMT-R Delayed Recall were significantly lower in both groups than in standardization
samples.
Comparison of Clinical Group Performance to similar Clinical Samples
Independent-samples t-tests were conducted to compare this study’s clinical group
demographics to those of similar clinical groups reported in each measure’s respective test
manual. Analyses did not reveal a significant difference between the mean age of the clinical
group and that of the WRAML2 clinical group (t(35) = -0.8824, p = .384, d = -.291). A chi-
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Table 11
Mean Differences between Clinical Group and Population Mean of 10 on Selected Visual
Memory Measures
Measure

Mean

SD

N

Mean

t

p

d

Difference
DM

5.70

2.23

20

-4.30

-8.636

< .001

-1.63

PM

8.00

2.62

20

-2.00

-3.419

0.003

-.71

DM Recognition

8.20

2.59

20

-1.80

-3.111

0.006

-.64

PM Recognition

8.70

2.85

20

-1.30

-2.041

0.055

-.44

VR I

5.60

3.65

20

-4.40

-5.395

< .001

-1.32

VR II

3.80

2.07

20

-6.20

-13.412

< .001

-2.41

4.89

3.63

20

-5.11

-6.294

< .001

-1.53

3.99

2.51

20

-6.02

-10.726

< .001

-2.17

BVMT-R
Immediate
BVMT-R
Delayed

Note. DM = Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2)
Design Memory; PM = WRAML2 Picture Memory; VR I = Wechsler Memory Scale, 4th
Edition (WMS-IV) Visual Reproduction I; VR II = WMS-IV Visual Reproduction II. Bold text
represents p that are significant at or below the .05 level; bold and italic text represents
correlations that are significant at or below the Bonferroni-corrected level of p = .006.

square test did not reveal a significant difference in gender between the two samples (χ2 =
2.2452, p = .134). The clinical group had a significantly greater level of education than the
WRAML2 clinical group (Fisher’s Exact Test, p = .0164). Analyses did not reveal a significant
difference between the mean age of the clinical group and the BVMT-R clinical group (t(59) =
1.9064, p = .062, d = .50). The mean level of education of the clinical group was significantly
greater than that of the BVMT-R clinical group (t(59) = 17.2600, p < .001, d = 1.11). There was
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Table 12
Comparison of Correlation Coefficients between Control Group and Normative Data Reported
by Test Authors
Measure 1

Measure 2

rstandard

rcontrol

z

p

DM

PM

.41

.58

-0.929

.176

DM Recognition

.54

.66

-0.772

.220

PM Recognition

.29

-.18

1.967

.025

DM Recognition

.26

.51

-1.214

.112

PM Recognition

.39

-.16

2.347

.010

DM Recognition

PM Recognition

.26

-.12

1.600

0.055

VR I

VR II

.66

.19

2.435

.008

BVMT-R Immediate

.68

.68

0.000

1.00

BVMT-R Delayed

.78

.17

3.542

< .001

PM

VR II

Note. DM = Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2)
Design Memory; PM = WRAML2 Picture Memory; VR I = Wechsler Memory Scale, Revised
Edition (WMS-R) Visual Reproduction I; VR II = WMS-R Visual Reproduction II. Bold text
represents correlation coefficients that are significant at or below the p = .05 level. WRAML2
inter-correlations are derived from a sample ranging in age from 9 to 89 years.

no significant difference between mean age of the clinical group and the WMS-IV AD clinical
group (t(66) = 0.4752, p = .636, d = .12). A chi-square test did not reveal a significant difference
in gender between the two samples (χ2 = 0.1276, p = .721). There was no significant difference
in level of education between the two samples (Fisher’s Exact Test, p = .942). The mean age of
the clinical group was significantly greater than that of the WMS-IV MCI clinical group (t(68) =
3.404, p = .001, d = .89). A chi-square test did not reveal a significant difference in gender
between the two samples (χ2 = 1.12, p = .290). There was no significant difference in level of
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Table 13
Comparison of Correlation Coefficients between Clinical Group and Normative Data Reported
by Test Authors
Measure 1

Measure 2

rstandard

rclinical

z

p

DM

PM

.41

-.17

2.480

.007

DM Recognition

.54

.22

1.554

.060

PM Recognition

.29

-.02

1.301

.097

DM Recognition

.26

.08

0.759

.224

PM Recognition

.39

.34

0.236

.407

DM Recognition

PM Recognition

.26

-.03

1.209

.113

VR I

VR II

.66

.09

2.848

.002

BVMT-R Immediate

.68

.52

1.025

.153

BVMT-R Delayed

.78

.20

3.416

< .001

PM

VR II

Note. DM = Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2)
Design Memory; PM = WRAML2 Picture Memory; VR I = Wechsler Memory Scale, Revised
Edition (WMS-R) Visual Reproduction I; VR II = WMS-R Visual Reproduction II. Bold text
represents correlation coefficients that are significant at or below the p = .05 level. WRAML2
inter-correlations are derived from a sample ranging in age from 9 to 89 years.

education between the two samples (Fisher’s Exact Test, p = .842). In the clinical group, all
means differed significantly from the standardization mean scaled score of 10. Tables 14, 15, and
16 compare means and SDs between this study’s clinical group and the clinical groups described
in each measure’s respective test manual. In summary, the clinical group in this study was more
highly educated than those conducted as part of the standardization studies for the WRAML2,
the BVMT-R, and the WMS-IV MCI group, while there was no difference in education when
compared to the AD group in the WMS-IV clinical study. No differences in age or gender were
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found between this study’s clinical group and the standardization clinical groups, with the
exception of the WMS-IV MCI group.

Table 14
Clinical Group Compared to AD Clinical Group reported in the WRAML2 Test Manual
WRAML2

Subtest/Index

Clinical Group

Clinical Group

Mean SD

Mean SD

n

n

Mean Difference

p

d

Design Memory

5.7

2.2 20

6.9

3.6 17

-1.2

.222 -.40

Picture Memory

8.0

2.6 20

6.1

3.4 16

1.9

.066 .63

Note. AD = Alzheimer’s disease; WRAML2 = Wide Range Assessment of Memory and
Learning, 2nd Edition.

Normative data from the WMS-IV Technical and Interpretive Manual (Wechsler, 2009)
were provided using separate groups for AD and MCI and are found in Table 15. The similarity
of demographic data and mean scaled scores between the clinical group in the current study and
the two WMS-IV clinical groups suggest that this current study’s clinical group more closely
resembles the WMS-IV AD clinical group than the MCI clinical group.
Overall, these comparative results indicate that the performance of the control group
differed fairly consistently from standardization group data reported by the tests’ authors.
Specifically, mean scaled scores for most measures were higher in this study’s control group
than in most standardization samples. Results generated using control group data should
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Table 15
Clinical Group Compared to MCI and AD Clinical Groups reported in the WMS-IV Test Manual

Subtest/Index

Clinical Group

WMS-IV Clinical

(MCI and AD)

Group (MCI or AD)

Mean

SD

n

Mean

Mean

SD

n

Difference

p

d

MCI Group*
VR I

5.6

3.6 20

8.7

3.0

50

-3.1

<.001 -.94

VR II

3.8

2.1 20

8.0

3.9

49

-4.2

<.001 -1.34

VR I

5.6

3.6 20

5.6

3.4

48

0.0

1.00

0.00

VR II

3.8

2.1 20

4.2

3.1

48

-0.4

.600

-.15

AD Group*

Note. MCI = mild cognitive impairment, AD = Alzheimer’s disease, WMS-IV = Wechsler
Memory Scale, 4th Edition, VR I = Visual Reproduction I, VR II = Visual Reproduction II.
* Because this study used a combined MCI/AD clinical group, comparisons were made between
this study’s clinical group and each of the two clinical groups (MCI and AD) reported
separately in the WMS-IV test manual.

therefore be interpreted with caution, as it may not represent a typical population of nonimpaired individuals. However, for the clinical group used in the current study, performance on
measures of visual memory was found reasonably similar to that of comparable clinical samples
reported in the respective test manuals. Of the eight comparisons made, two comparisons
indicated that the clinical group in the present study was less impaired than the clinical group
studied by the measure’s authors. Two comparisons found an equivalent performance between
clinical groups. Four comparisons demonstrated that the clinical group in the present study was
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Table 16
Clinical Group Compared to AD Clinical Group reported in the BVMT-R Test Manual

Subtest/Index

Clinical

BVMT-R Clinical

Group

Group

Mean SD n

Mean

SD

n

Mean Difference

p

d

Total Recall

4.9

3.6 20

6.2

3.5

41

-1.3

.182 -.37

Delayed Recall

4.0

2.5 20

1.5

1.5

41

2.5

<.001 1.21

Note. BVMT-R = Brief Visuospatial Memory Test, Revised Edition.

more impaired. However, two of these comparisons were between an MCI group (WMS-IV) and
the present study’s clinical group. Ignoring these two comparisons, no differences were
significant with the exception of BVMT-R Delayed Recall. Performance on this measure was
significantly greater in the present study’s clinical group than in the clinical group studied by the
author. Results suggest that the performance of the clinical group on selected memory measures
in this study is similar to that of individuals with memory impairment due to AD in other clinical
samples. The clinical group in this study is representative of the typical population of individuals
who undergo memory testing and are found to have AD. Comparisons between the performance
of this study’s clinical group and groups described in the respective tests’ manuals can therefore
be interpreted and generalized to this population.
Hypotheses 1 and 2: Relatedness Among Visual Memory Measures
As found in Table 17, correlations between measures were higher overall in the control
group (M = .289, SD = .350) than in the clinical group (M = .157, SD = .299). Eleven of the 28
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Table 17
Intercorrelations of Scaled Score Performance for the Control and Clinical Groups
Subtest

1

1. WRAML2 Design Memory

2

3

4

5

6

7

8

.580 .661 -.178 .328 .526 .508 .122

2. WRAML2 Picture Memory

-.172

.512 -.159 .534 .538 .647 .435

3. WRAML2 Design Memory Recognition

.221 .078

4. WRAML2 Picture Memory Recognition

-.023 .339 -.034

5. WMS-IV Visual Reproduction I

.749 -.221 .316 .008

6. WMS-IV Visual Reproduction II

-.073 .282 -.061 .141 .094

7. BVMT-R Total Recall

.426 -.115 .074 -.335 .516 .117

8. BVMT-R Delayed Recall

.512 -.026 .273 -.271 .518 .204 .871

-.124 .227 .189 .647 .262
-.177 -.190 -.269 -.421
.189 .677 .711
.329 .171
.825

Note. Unshaded = clinical group, shaded = control group; bold text indicates significance at or
less than the p = .05 level; bold and italic text indicates significance at or less than the p = 0.002
level. WRAML2 = Wide Range Assessment of Memory and Learning, 2nd Edition; WMS-IV =
Wechsler Memory Scale, 4th Edition; BVMT-R = Brief Visuospatial Memory Test, Revised
Edition.

correlations were significant for the control group, while only six were significant for the clinical
group. Given the moderate to strong correlations between demographic variables and scaled
scores shown in Table 18, these values may be misleading. Relationships between measures
appear to be strongly influenced by demographic variables, and it is not clear from this table the
extent to which the measures are related on their own. To control for the influence of age,
education, and IQ, partial correlations were calculated for each group. The obtained partial
correlations are shown in Table 19. In the control group, partial correlations between measures
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became stronger after controlling for demographic variables. This is likely due to the
homogeneity of the sample in terms of level of education and estimated premorbid IQ.

Table 18
Correlations between Visual Memory Mean Scaled Scores and Demographic Variables by
Group
Group

Overall

Clinical

Control

Measure

Age

Ed

IQ

Age

Ed

IQ

Age

Ed

IQ

DM

-.385

.366

.518

.013

.186

.307

-.338

.150

.559

PM

-.402

.244

.261

.065

.019

-.024

-.624

.108

.255

DM Recognition

-.372

.247

.214

-.288

.182

-.037

-.112

-.090

.044

PM Recognition

-.243

.006

.223

-.220

-.325

-.030

.310

-.077

.171

VR I

-.357

.478

.387

.023

.329

.298

-.301

.341

-.054

VR II

-.422

.258

.381

.257

-.141

-.073

-.588

-.044

.409

-.493

.420

.461

-.176

.400

.416

-.495

.039

-.032

-.483

.369

.379

-.097

.316

.512

-.466

.064

-.274

BVMT-R
Immediate
BVMT-R
Delayed

Note. Ed = years of education; DM = Wide Range Assessment of Memory and Learning, 2nd
Edition (WRAML2) Design Memory; PM = WRAML2 Picture Memory; VR I = Wechsler
Memory Scale, 4th Edition (WMS-IV) Visual Reproduction I; VR II = WMS-IV Visual
Reproduction II; BVMT-R = Brief Visuospatial Memory Test, Revised Edition.

Recognition measures. Partial correlations were also calculated for raw scores on Visual
Reproduction Recognition and BVMT-R Recognition Hits. The two subtests were moderately
and positively correlated to each other in the clinical group (r =.335), although this result was not
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Table 19
Partial Intercorrelations of Scaled Score Performance for the Control and Clinical Groups
Subtest
Subtest

1

1. WRAML2 Design Memory

2

3

4

5

6

7

8

.608 .761 -.397 .622 .337 .750 .512

2. WRAML2 Picture Memory

-.180

.561 .063 .589 .251 .509 .256

3. WRAML2 Design Memory Recognition

.263 .093

4. WRAML2 Picture Memory Recognition

.023 .431 -.041

5. WMS-IV Visual Reproduction I

.732 -.249 .350 .159

6. WMS-IV Visual Reproduction II

.164 .279 .020 .204 .130

7. BVMT-R Immediate Recall

.785 -.122 .021 -.351 .435 .229

8. BVMT-R Delayed Recall

.687 -.017 .330 -.318 .445 .314 .851

-.127 .308 .097 .740 .363
.091 -.194 .006 -.056
.343 .677 .681
.139 .095
.786

Note. Unshaded = clinical group, shaded = control group; bold text indicates significance at or
below the p = .05 level; bold and italic text indicates significance at or below the p = 0.0018
level. WRAML2 = Wide Range Assessment of Memory and Learning, 2nd Edition; WMS-IV =
Wechsler Memory Scale, 4th Edition; BVMT-R = Brief Visuospatial Memory Test, Revised
Edition.

statistically significant (p = .189). The two subtests were moderately and positively correlated to
each other in the control group, as well (r = .542), and this result reached significance (p = .025).
Overall, measures are more strongly correlated in the control group than in the clinical
group, even after controlling for the influence of age, education, and estimated premorbid IQ. It
is not clear whether or why these differences exist, but it is possible that they may reflect
differences in variability between the groups, i.e., the relative homogeneity of the control group
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versus the difference in scores in the clinical group, in which participants presumably have
differing levels of impairment and therefore a wider range of performance on each measure.
Indeed, standard deviations for most measures are greater in the clinical group than in the control
group.
Hypotheses 3 and 4: Comparisons of Mean Scaled Scores between Measures
It was hypothesized that different measures of visual memory are equivalent. Given the
moderate to strong relationships between some of the visual memory measures (Tables 17 and
19), one way to demonstrate equivalence between measures is to assume that two measures are
measuring the same construct when they are strongly correlated. A significant correlation
between two measures would indicate that the two measures are measuring the same construct in
a similar fashion. Correlation coefficients in bold text (with or without italics) in Tables 17 and
19 indicate that the two measures were found to be strongly correlated and therefore equivalent
within each group in the present study. Because there were 28 correlations, however, a
Bonferroni correction was necessary to reduce the likelihood of Type I error; consequently, using
an using an α of .05 / 28 = .0018, those correlation coefficients that are bolded and italicized in
Table 19 can be considered equivalent to each other within a similar group of patients/controls.
Of note is that the strongest correlations were found between free-recall measures in the clinical
group (WRAML2 Design Memory, WMS-IV Visual Reproduction I, and BVMT-R Immediate
and Delayed Recall). An interesting finding is the strength of the correlation between BVMT-R
Immediate and Delayed Recall scores in the clinical group. Either participants in the clinical
group performed equally poorly on both measures, or the measures are sufficiently similar as to
be redundant.
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When making comparisons between groups, another way to demonstrate equivalence is to
compare the strength of the correlation between two measures within each subgroup. If the
correlation coefficient between two measures in one group does not differ significantly from the
correlation coefficient between the same two measures in the other group, the measures may be
considered equivalent in that group. A significant difference in the strength of the two
correlations would therefore imply that two measures are not equivalent according to this
criterion. To determine which measures were equivalent according to this criterion, partial
correlations were converted to z scores using a Fisher transformation. The strength of the
relationship between several pairs of measures differed significantly between groups (Table 20),
suggesting that the pair of measures may not be considered equivalent, at least in this particular
sample. Using a Bonferroni-corrected α of .0018, however, no differences between partial
correlation coefficients were significant.
By this metric, large differences between correlation coefficients were found between
groups for the following pairs of measures: WRAML2 Design Memory and Picture Memory;
WRAML2 Design Memory and Design Memory Recognition; WRAML2 Picture Memory and
WMS-IV Visual Reproduction I; WRAML2 Picture Memory and BMVT-R Immediate Recall;
and WRAML2 Design Memory Recognition and BVMT-R Immediate Recall. Notably, all of
these pairs of measures differ in terms of either item content, response format, or both; no
significant differences between correlations were found for pairs of measures that are similar in
content and structure (e.g., WRAML2 Design Memory and WMS-IV Visual Reproduction I).
When comparing normal to impaired groups, another way to determine equivalence
between measures is to compare the degree to which the mean scaled scores on each measure
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Table 20
Comparison of Partial Correlation Coefficients of Clinical and Control Groups
Measure 1
DM

Measure 2

rclinical

rcontrol

z

p

PM

-.180

.608

-2.59

.005

DM Recognition

.263

.761

-2.13

.017

PM Recognition

.023

-.397

1.29

.099

VR I

.732

.622

0.60

.275

VR II

.164

.337

-0.54

.295

.785

.750

0.25

.402

Delayed

.687

.512

0.81

.210

DM Recognition

.093

.561

-1.58

.057

PM Recognition

.431

.063

1.16

.123

VR I

-.249

.589

-2.71

.003

VR II

.279

.251

0.09

.466

-.122

.509

-1.99

.023

Delayed

-.017

.256

-0.81

.208

PM Recognition

-.041

-.127

0.25

.400

VR I

.350

.308

0.14

.446

VR II

.020

.097

-0.23

.411

.021

.740

-2.71

.003

Delayed

.330

.363

-0.11

.457

VR I

.159

.091

0.20

.420

BVMT-R
Immediate
BVMT-R
PM

BVMT-R
Immediate
BVMT-R
DM Recognition

BVMT-R
Immediate
BVMT-R
PM Recognition
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Table 20 Continued
Measure 1

Measure 2

rclinical

rcontrol

z

p

.204

-.194

1.18

.120

-.351

.006

-1.09

.139

Delayed

-.318

-.056

-0.80

.213

VR II

.130

.343

-0.66

.254

.435

.677

-1.04

.149

.445

.671

-0.97

.165

.229

.139

0.27

.393

.314

.095

0.67

.251

.851

.786

0.58

.281

VR II
BVMT-R
Immediate
BVMT-R
VR I

BVMT-R
Immediate
BVMT-R
Delayed
BVMT-R
VR II

Immediate
BVMT-R
Delayed
BVMT-R

BVMT-R Immediate

Delayed

Note. Bold text represents correlation coefficients that are significant at or below the p = .05
level. DM = Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2)
Design Memory; PM = WRAML2 Picture Memory; VR I = Wechsler Memory Scale, Revised
Edition (WMS-R) Visual Reproduction I; VR II = WMS-R Visual Reproduction II.

differ between groups. By definition, patients with AD exhibit some degree of memory
impairment. Participants in this study were grouped according to the presence or absence of a
diagnosis of AD. The clinical group was expected to perform below the level of the control
group, although it was not known to what degree they would underperform. For practical
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purposes, any measure whose mean scaled scores differ significantly between groups of
memory-impaired and presumably memory-unimpaired participants can be considered
equivalent to any other measure that meets such a criterion. In other words, if the clinical goal is
to document impairment in memory as defined by performance on a measure that deviates
significantly from a population mean, any measure that reliably does so can be used. In order to
make these comparisons, independent-samples t-tests were conducted. Using a Bonferronicorrected α of .05 / 8 = .006, mean scaled scores differed significantly between groups on all
measures for which scaled scores were derived (p < .001)
Levene’s Test for Equality of Variances was significant for Picture Memory Recognition,
(p = .021), and for BVMT-R Delayed (p = .016). Therefore, Mann-Whitney independentsamples U-tests were conducted. Mean scaled scores on Picture Memory Recognition were
significantly greater in the control group than in the clinical group (U(38) = 67.5, z = -3.619, p <
.001), and mean scaled scores on BVMT-R Delayed were significantly greater in the control
group than in the clinical group (U(38) = 44.0, z = -4.226, p < .001). By this metric, therefore,
each measure demonstrates reliable differences between normal and impaired groups.
Yet another way to demonstrate equivalence between measures is to show that mean
scaled scores for different measures differ equally between groups but not within groups. In other
words, if mean scaled scores do not differ significantly between measures within a particular
group, measures can be considered equivalent in the sense that each one will yield the same
conclusion when used alone to determine the relative strength or weakness of a participant’s
performance relative to a control group of normal healthy volunteers (as in the standardization
samples for each measure).
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A 2 × 8 mixed within-between groups repeated-measures analysis of variance was
conducted in order to determine whether there were meaningful differences between measures in
the overall sample and within each subgroup. This method compares the differences in mean
scaled scores between measures to each other, both in the entire sample and within or between
each subgroup, thereby determining whether any of these differences are statistically significant.
The assumption of equal dependent variable covariance matrices across groups was met (Box’s
M = 76.101, F(36,4859) = 1.632, p = .010). The assumption of sphericity was violated
(Mauchly’s W = .094, p < .001). Therefore, multivariate tests were used in the analysis. There
was a significant within-subjects main effect for measure (Wilks’ λ = .308, F(7,32) = 10.265, p <
.001, partial η2 = .692), with a power to detect significance of 1.000. There was a significant
between-subjects main effect (F(1) = 84.644, p < .001, partial η2 = .690), with a power to detect
significance of 1.000. There was a significant within-between interaction effect (Wilks’ λ = .545,
F(7,32) = 3.822, p = .004, partial η2 = .455), with a power to detect significance of .948. This
interaction suggests that differences observed between mean scaled scores on visual memory
measures between groups do vary (as can be seen in Figure 1); however, since paired
comparisons show each test’s result is significantly different between groups, the significant
main effect of group can be interpreted. Results of the ANOVA indicate that the differences
observed between mean scaled scores on visual memory measures are strongly influenced by
group membership (i.e., diagnosis). While there is a difference in level of performance between
measures, the significant interaction effect limits the interpretability of this finding.
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Figure 1. Mean Scaled Scores on Visual Memory Measures by Group.
Note. DM = Wide Range Assessment of Memory and Learning, 2nd Edition (WRAML2)
Design Memory; PM = WRAML2 Picture Memory; VR I = Wechsler Memory Scale, 4th
Edition (WMS-IV) Visual Reproduction I; VR II = WMS-IV Visual Reproduction II; BVMTR = Brief Visuospatial Memory Test, Revised Edition.

Because of the moderate to strong correlations that were found between demographic
variables (age, education, estimated premorbid IQ) and the visual memory measures, and
because those demographic variables differed significantly between groups, a 2 × 8 mixed
within-between groups repeated-measures analysis of covariance controlling for age, education,
and premorbid IQ was conducted in order to determine whether an interaction effect or any main
effects would remain after controlling for those variables. The assumption of equal dependent
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variable covariance matrices across groups was met (Box’s M = 76.101, F(36,4859) = 1.632, p =
.010). The assumption of sphericity was violated (Mauchly’s W = .094, p < .001). Therefore,
multivariate tests were used in the analysis. There was no significant within-subjects main effect
for measure (Wilks’ λ = .843, F(7,29) = 0.774, p = .614, partial η2 = .157). However, the withinsubjects analysis yielded a power to detect significance of only .272 at an α level of .05,
indicating that the sample size was not sufficiently large to detect a difference between measures
after removing covariates. There was a significant between-subjects main effect (F(1) = 50.364,
p < .001, partial η2 = .590), with a power to detect significance of 1.000. There was a significant
within-between interaction effect (Wilks’ λ = .630, F(7,29) = 2.435, p = .043, partial η2 = .370),
with an observed power to detect significance of .771 at an α level of .05, suggesting that
differences observed between mean scaled scores on visual memory measures are strongly
influenced by group membership, even after removing covariates. It appears likely that group
membership is the source of the differences between mean scaled scores on each measure when
measures are compared within the entire sample. Pair-wise comparisons indicate that some of the
largest between-groups differences were found between WMS-IV Visual Reproduction II and
WRAML2 subtests, as shown in Table 21.
As previously mentioned, the significant interaction effect observed suggests that mean
scaled scores differ between visual memory measures to varying degrees depending on group
membership. In order to identify the specific measures that contributed to this effect, 1 × 8
repeated-measures ANOVAs were conducted for each group. For the clinical group, the
assumption of sphericity was violated (Mauchly’s W = .018, p < .001). Therefore, multivariate
tests were used in the analysis. There was a significant main effect for measure (Wilks’ λ = .142,
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Table 21
Pair-wise Comparisons between Measures in the Overall Sample Controlling for Age,
Education, and Estimated Premorbid IQ
Measure 1

Measure 2

DM

PM

DM Recognition

PM Recognition

VR I

Mean Difference

p

PM

-1.575

.081

DM Recognition

-1.875

.001

PM Recognition

-2.125

.012

VR I

-0.875

1.00

VR II

0.975

.749

BVMT-R Immediate

-0.495

1.000

BVMT-R Delayed

0.344

1.000

DM Recognition

-0.300

1.000

PM Recognition

-0.550

1.000

VR I

0.700

1.000

VR II

2.550

< .001

BVMT-R Immediate

1.081

1.000

BVMT-R Delayed

1.919

.110

PM Recognition

-0.250

1.000

VR I

1.000

1.000

VR II

2.850

< .001

BVMT-R Immediate

1.381

.537

BVMT-R Delayed

2.219

.029

VR I

1.250

1.000

VR II

3.100

< .001

BVMT-R Immediate

1.631

.970

BVMT-R Delayed

2.469

.066

VR II

1.850

.153

BVMT-R Immediate

0.381

1.000
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Table 21 Continued
Measure 1

VR II
BVMT-R Immediate

Measure 2

Mean Difference

p

BVMT-R Delayed

1.219

.494

BVMT-R Immediate

-1.470

.486

BVMT-R Delayed

-0.631

1.000

BVMT-R Delayed

0.839

.668

Note. Bold text represents correlation coefficients that are significant at or below the p = .05
level after using a Bonferroni correction for multiple comparisons. DM = Wide Range
Assessment of Memory and Learning, 2nd Edition (WRAML2) Design Memory; PM =
WRAML2 Picture Memory; VR I = Wechsler Memory Scale, Revised Edition (WMS-R)
Visual Reproduction I; VR II = WMS-R Visual Reproduction II.

F(7,13) = 11.182, p < .001, partial η2 = .858), with a power to detect significance of 1.00. For the
control group, the assumption of sphericity was violated (Mauchly’s W = .023, p < .001).
Therefore, multivariate tests were used in the analysis. The main effect for measure was not
significant (Wilks’ λ = .444, F(7,13) = 2.321, p = .09, partial η2 = .556), with a power to detect
significance of .615. Pair-wise comparisons are shown in Table 22.
In the clinical group, the mean scaled score for the BVMT-R Delayed Recall was
significantly lower than the mean scaled score for all four of the WRAML2 measures, and the
mean scaled score for WMS-IV Visual Reproduction II was significantly lower than the mean
scaled score for WRAML2 Design Memory Recognition, Picture Memory, and Picture Memory
Recognition. In the control group, no mean scaled scores differed significantly. Pair-wise
comparisons are shown in Table 23.
The large difference in scores between WRAML2 subtests and the other two delayed
recall subtests suggests that the WRAML2 may exhibit better measurement characteristics at
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Table 22
Pairwise Comparisons between Measures in the Control Group
Measure 1

Measure 2

DM

PM

DM Recognition

PM Recognition

VR I

Mean Difference

p

PM

-0.850

1.000

DM Recognition

-1.250

.523

PM Recognition

-1.250

1.000

VR I

-1.850

1.000

VR II

0.050

1.000

BVMT-R Immediate

-1.797

.537

BVMT-R Delayed

-1.027

1.000

DM Recognition

-0.400

1.000

PM Recognition

-0.400

1.000

VR I

-1.000

1.000

VR II

0.900

1.000

BVMT-R Immediate

-0.947

1.000

BVMT-R Delayed

-0.177

1.000

PM Recognition

0.000

1.000

VR I

-0.600

1.000

VR II

1.300

1.000

BVMT-R Immediate

-0.547

1.000

BVMT-R Delayed

0.223

1.000

VR I

-0.600

1.000

VR II

1.300

1.000

BVMT-R Immediate

-0.547

1.000

BVMT-R Delayed

0.223

1.000

VR II

1.900

1.000

BVMT-R Immediate

0.054

1.000

BVMT-R Delayed

0.823

1.000
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Table 22 Continued
Measure 1

Measure 2

VR II
BVMT-R Immediate

Mean Difference

p

BVMT-R Immediate

-1.847

.858

BVMT-R Delayed

-1.077

1.000

BVMT-R Delayed

0.770

1.000

Note. Bold text represents correlation coefficients that are significant at or below the p = .05
level after using a Bonferroni correction for multiple comparisons. DM = Wide Range
Assessment of Memory and Learning, 2nd Edition (WRAML2) Design Memory; PM =
WRAML2 Picture Memory; VR I = Wechsler Memory Scale, Revised Edition (WMS-R)
Visual Reproduction I; VR II = WMS-R Visual Reproduction II.

lower levels of performance. In order to determine whether differences exist between the AD and
MCI subgroups within the clinical group (which, presumably, should perform somewhat
differently due to differing levels of impairment), independent-samples t-tests were conducted
using a Bonferroni correction for multiple comparisons. When comparing the 6 participants in
the clinical group who were diagnosed with MCI to the 14 who were diagnosed with AD, no
differences between means were found for any of the visual memory measures, most likely due
to the small number of participants in each group. Effect sizes, while modest, suggest that,
although WRAML2 Picture Memory and Picture Memory Recognition scaled scores were higher
than scaled scores on the other measures within the clinical group, they better differentiated
between the small AD and MCI subgroups within the clinical group.
A 2 × 8 mixed within-between repeated-measures analysis of covariance controlling for
age, education, and estimated premorbid IQ was conducted within the clinical group to determine
whether there were any differences in performance between those participants diagnosed with
AD versus those diagnosed with MCI. The within-subjects main effect for measure approached
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Table 23
Pairwise Comparisons between Measures in the Clinical Group
Measure 1

Measure 2

DM

PM

DM Recognition

PM Recognition

VR I

Mean Difference

p

PM

-2.30

.342

DM Recognition

-2.50

.042

PM Recognition

-2.00

.046

VR I

0.10

1.000

VR II

1.90

.203

BVMT-R Immediate

0.81

1.000

BVMT-R Delayed

1.72

.012

DM Recognition

-0.20

1.000

PM Recognition

-0.70

1.000

VR I

2.40

1.000

VR II

4.20

< .001

BVMT-R Immediate

3.11

.230

BVMT-R Delayed

4.02

.003

PM Recognition

-0.50

1.000

VR I

2.60

.164

VR II

4.40

< .001

BVMT-R Immediate

3.31

.077

BVMT-R Delayed

4.22

< .001

VR I

3.10

.203

VR II

4.90

< .001

BVMT-R Immediate

3.81

.130

BVMT-R Delayed

4.72

.003

VR II

1.80

1.000

BVMT-R Immediate

0.71

1.000

BVMT-R Delayed

1.62

.981
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Table 23 Continued
Measure 1

Measure 2

VR II
BVMT-R Immediate

Mean Difference

p

BVMT-R Immediate

-1.09

1.000

BVMT-R Delayed

-0.19

1.000

BVMT-R Delayed

0.91

1.000

Note. Bold text represents correlation coefficients that are significant at or below the p = .05
level after using a Bonferroni correction for multiple comparisons. DM = Wide Range
Assessment of Memory and Learning, 2nd Edition (WRAML2) Design Memory; PM =
WRAML2 Picture Memory; VR I = Wechsler Memory Scale, Revised Edition (WMS-R)
Visual Reproduction I; VR II = WMS-R Visual Reproduction II.

significance (Wilks’ λ = .320, F(7,9) = 2.735, p = .081, partial η2 = .680), with a power to detect
significance of .603. There was no significant between-subjects main effect (F(1) = 0.332, p =
.573, partial η2 = .022), with a power to detect significance of .084. There was no significant
within-between interaction effect (Wilks’ λ = .619, F(7,9) = 0.790, p = .613, partial η2 = .381),
with a power to detect significance of .190. Results are shown in Table 24.
Recognition measures. To compare those recognition tasks for which scaled scores
could not be derived (WMS-IV and BVMT-R), receive-operator characteristic (ROC) curves
were conducted on subtest raw scores. Briefly, ROC curves compare the diagnostic accuracy of a
test in determining whether a participant belongs to a certain group (e.g., normal or impaired)
according to a given cut score (Hanley & McNeil, 1983). The ROC curve analyses compare each
measure’s ability to classify participants into one or the other group; classification accuracy
(sensitivity and specificity) can then be compared between measures. In most cases, a measure
may be considered clinically useful if its sensitivity and specificity both exceed 80%, although
there are reasons why different cut scores may be selected to minimize false positives or false
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Table 24
Mean Scaled Score Differences between AD and MCI Patients in the Clinical Group
AD

MCI

Mean

Measure

Mean

SD

N

Mean

SD

N

difference

p

d

DM

5.57

2.344

14

6.00

2.098

6

0.429

.704

-.19

PM

8.36

2.620

14

7.17

2.639

6

-1.190

.365

.45

Recognition

8.00

2.828

14

8.67

2.066

6

0.667

.611

-.27

PM Recognition

8.21

2.359

14

9.83

3.764

6

1.619

.255

-.52

VR I

5.64

4.144

14

5.50

2.429

6

-0.143

.939

.04

VR II

4.07

1.900

14

3.17

2.483

6

-0.905

.384

.41

4.69

3.640

14

5.37

3.898

6

0.682

.711

-.18

3.86

2.682

14

4.29

2.247

6

0.429

.736

-.17

DM

BVMT-R
Immediate
BVMT-R
Delayed

Note. AD = Alzheimer’s disease; MCI = mild cognitive impairment; DM = Wide Range
Assessment of Memory and Learning, 2nd Edition (WRAML2) Design Memory; PM =
WRAML2 Picture Memory; VR I = Wechsler Memory Scale, Revised Edition (WMS-R)
Visual Reproduction I; VR II = WMS-R Visual Reproduction II.

negatives (Matthews & Farewell, 2007). Equivalence between recognition measures can be
demonstrated if no significant differences in classification accuracy can be demonstrated.
Raw scores for WMS-IV Visual Reproduction Recognition, BVMT-R Hits, BVMT-R
False Alarms, and BVMT-R Discrimination were compared using MedCalc. For Visual
Reproduction Recognition, using a cut score of ≤ 4 correct (out of 7 multiple-choice items)
yielded an area under the curve (AUC) of .988 (Youden’s J = .90, p < .001, sensitivity = 90%,
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specificity = 100%). For BVMT-R Hits, using a cut score of ≤ 4 (out of 6 yes-no items) yielded
an AUC of .620 (Youden’s J = .20, p = .180, sensitivity = 30%, specificity = 90%). For BVMTR False Alarms, using a cut score of 0 (i.e., a score of ≥ 1 classifies a participant as normal)
yielded an AUC of .831 (Youden’s J = .60, p < .001, sensitivity = 80%, specificity = 80%). For
BVMT-R Discrimination Index, using a cut score of ≤ 4 yielded an AUC of .840 (Youden’s J =
.50, p < .001, sensitivity = 70%, specificity = 80%). Tables 25 and 26 summarize the sensitivity
and specificity characteristics of WMS-IV Visual Reproduction Recognition and BVMT-R
Recognition False Alarms, which where the only two measures that yielded cut scores with
clinically-adequate characteristics.

Table 25
Sensitivity and Specificity of WMS-IV Visual Reproduction Recognition Raw Scores
Cut Score

Sensitivity (%)

Specificity (%)

0

0

100

≤4

90

100

≤5

100

75

≤7

100

0

Note: WMS-IV = Wechsler Memory Scale, 4th Edition

Comparisons were made between AUCs in order to determine whether any recognition
measure was significantly better at classifying participants. The AUC for Visual Reproduction
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Table 26
Sensitivity and Specificity of BVMT-R Recognition False Alarms Raw Scores
Cut Score

Sensitivity (%)

Specificity (%)

0

100

0

≥1

80

80

≥2

45

95

≥3

25

100

≥5

0

100

Note: BVMT-R = Brief Visuospatial Memory Test, Revised Edition

Recognition was significantly greater than for BVMT-R Hits (difference = 0.368, p < .001), for
BVMT-R False Alarms (difference = 0.156, p = .020), and for BVMT-R Discrimination Index
(difference = 0.148, p = .015). The area under the curve for BVMT-R Hits was significantly
smaller than for BVMT-R False Alarms (difference = -0.211, p = .032) and for BVMT-R
Discrimination Index (difference = -0.220, p < .001). The AUCs did not differ significantly
between BVMT-R False Alarms and BVMT-R Discrimination (difference = -0.009, p = .892).
Of the recognition measures, Visual Reproduction Recognition most accurately classified
normal and impaired participants in this sample. Using a cut score of ≤ 4 out of 7 correct
responses (raw score), 90% of participants in the clinical group were correctly classified as
impaired, and 100% of participants in the control group were classified as normal. In addition, a
cut score of 0 on BVMT-R False Alarms (i.e., there were no ‘Yes’ responses to “foil” items that
were not present on the original stimulus card) accurately classified 80% of participants as
impaired when they belonged to the clinical group, and 80% of participants as normal when they
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belonged to the control group. This approaches the balance of sensitivity and specificity
observed among well-validated screening measures (Nasreddine et al., 2005; Solomon et al.,
2014), suggesting a potential real-world application of that cut score. If the recognition portion of
the BVMT-R is administered, a single false positive suggests the presence of memory
impairment, at least in this small sample.
Overall, results of the ROC curve analyses suggest that the recognition measures are not
equivalent. WMS-IV Visual Reproduction Recognition and BVMT-R Recognition False Alarms
outperformed the other recognition measures for which scaled scores could not be derived
(comparisons were not made between these measures and the WRAML2 recognition measures,
which were grouped with the other measures for which scaled scores were available).
The WRAML2 Picture Memory subtest is based on recognition of changes between
drawings, rather than on recall of the drawings themselves. Because random guessing may
influence performance on this subtest, the number of commission errors made on the task was
compared between groups. An independent-samples t-test found no significant difference in
commission errors between groups (t(38) = -0.733, p = .468, d = .23). A receiver-operator
characteristic (ROC) curve analysis yielded an area under the curve (AUC) of .525 (p = .79). At
a cut score of ≥ 5, the number of commission errors distinguished normal from impaired
participants with a sensitivity of 35% and a specificity of 80% (Youden’s J = .15). These results
suggest that both groups made about the same number of commission errors, on average, and
commission errors do not appear to have exerted a significant influence on performance on this
task.
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Chapter 4
Discussion

The purpose of the study was to determine whether there was clinical equivalence among
several commonly used visual memory measures, using patients with Alzheimer’s disease or
mild cognitive impairment, and a comparison, non-clinical age-matched group. While there are
many ways to define equivalence, in this study four specific criteria for equivalence were
explored: (a) correlations between measures; (b) similarity of correlations between measures in
two groups; (c) differences between mean scaled scores between groups; and (d) differences
between differences in mean scaled scores between groups. Each hypothesis aimed to compare
selected visual memory measures according to each criterion for equivalence.
Hypothesis 1 stated that visual memory measures would be found to be significantly
correlated. In general, the results of this study are consistent with test norming studies that report
moderate to strong relationships between various visual memory measures (Benedict, 1997;
Sheslow & Adams, 2003; Wechsler, 2009). The average r in the control group was .40, as
compared to the average r in the clinical group of .29 (this was computed by subtracting the r for
the control group from the r for the clinical group and averaging the absolute value of all
difference scores). The following pairs of measures were strongly and positively correlated in the
control group: WRAML2 Design Memory and Picture Memory; WRAML2 Design Memory and
Design Memory Recognition; WRAML2 Design Memory and WMS-IV Visual Reproduction I;
WRAML2 Design Memory and BVMT-R Immediate Recall; WRAML2 Picture Memory and
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Design Memory Recognition; WRAML2 Picture Memory and WMS-IV Visual Reproduction I;
WRAML2 Picture Memory and BVMT-R Immediate Recall; WRAML2 Design Memory
Recognition and BVMT-R Immediate Recall; WMS-IV Visual Reproduction I and BVMT-R
Immediate Recall; and WMS-IV Visual Reproduction I and BVMT-R Delayed Recall (Table
19). Thus, all of the immediate recall measures were strongly and positively correlated in the
control group, providing evidence of convergent validity in a group of normal controls.
According to the first criterion, these measures can be considered equivalent in a group of
normal controls. Clinically, this adds to the existing literature suggesting that the selected visual
memory measures measure the same construct despite differences in item content and response
format.
While correlations were generally not as strong in the clinical group, strong positive
correlations were found between the following pairs of measures: WRAML2 Design Memory
and WMS-IV Visual Reproduction I; WRAML2 Design Memory and BVMT-R Immediate
Recall; WRAML2 Design Memory and BVMT-R Delayed Recall; and BVMT-R Immediate and
Delayed Recall. Clinically, this suggests that WRAML2 Design Memory, WMS-IV Visual
Reproduction I, and the BVMT-R are equivalent according to the first criterion. The use of any
of those measures will yield very similar scores in a group of patients with MCI and early AD,
and it would not necessarily be beneficial to use both. However, because of the much weaker
correlations between each of those measures’ delayed retrieval components (Table 19), and
because delayed retrieval is critical aspect of memory evaluation (Sheslow & Adams, 2003;
Budson & Solomon, 2011), the results of this analysis cannot be used to make decisions about
whether to use any or all of the delayed retrieval trials.
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Hypothesis 2 stated that the strength of the relationships between different memory
measures do not differ between clinical and non-clinical groups. Equivalence between measures
would be demonstrated by a lack of difference between correlation coefficients. The results of
this study provide reasonable grounds to reject this hypothesis. Differences were found in the
strength of the relationships between some pairs of measures between groups. The average of the
between-groups differences in correlation coefficients was .28 (again computed by subtracting
the r for the control group from the r for the clinical group and averaging the absolute value of
all difference scores). More specifically, correlations between WRAML2 Design Memory and
Picture Memory, between WRAML2 Design Memory and Picture Memory Recognition,
between WRAML2 Picture Memory and WMS-IV Visual Reproduction I, between WRAML2
Picture Memory and BVMT-R Immediate Recall, and between WRAML2 Design Memory
Recognition and BVMT-R Immediate Recall were stronger in the control group than in the
clinical group.
When making decisions between measures in the clinical setting, the measures that are
most strongly correlated are more likely to be considered “equivalent” or “interchangeable, but
this depends on the strength of the correlation. Thus, while Hypothesis 2 was rejected, it is not
clear whether the results of the comparison between correlations between groups are sufficiently
useful from a clinical perspective. Given the restricted range of scores in the clinical group, the
strength of the correlations between the 3 immediate recall measures (WRAML2 Design
Memory, WMS-IV Visual Reproduction I, and BVMT-R Immediate Recall) provide ample
evidence that these measures are “equivalent” in a group of memory-impaired patients. However,
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the fact that the correlations are equally strong in the control group provides evidence for
equivalence according to this criterion.
Hypothesis 3 stated that for each measure, mean scaled scores were expected to differ
between the clinical group and the control group. The results of this study definitively support
this hypothesis. Differences in mean scaled scores between the clinical group and the control
group ranged from 2.8 to 7.2 scaled score points, with corresponding effect sizes ranging from
1.26 to 2.77 (Table 9). Differences between mean scaled scores in the clinical group and a
population mean scaled score of 10 ranged from 1.3 scaled score points on WRAML2 Picture
Memory Recognition to 6.2 on WMS-IV Visual Reproduction II, with an average difference of
3.89 (Table 11). In general, differences were larger on the free recall measures, and in particular
on the delayed recall measures. Thus, with the exception of WRAML2 Picture Memory
Recognition, the performance of the clinical group on each measure fell below 1.5 scaled score
points from the mean, a difference that represents a commonly-accepted criterion for memory
impairment (i.e., 1.5 standard deviations below the mean; Budson & Solomon, 2011). Clinically,
these results suggests that WRAML2 Design Memory, WMS-IV Visual Reproduction (I and II),
and BVMT-R (Immediate and Delayed Recall) are equivalent in terms of their ability to
document and quantify memory weaknesses in patients with memory impairment. Measures that
rely on recognition (WRAML2 Picture Memory and the two WRAML2 delayed recognition
measures) should only be used as adjuncts to one of the three recall-based measures, and not as a
primary indicator of memory impairment.
Hypothesis 4 stated that differences between measures are larger in the clinical group
than in the control group. Given the homogeneity of the control group, it is not surprising that
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few differences were found between mean scaled scores across measures. This is a group of
participants whose performance on memory measures should be average or above average for
their age group. Accordingly, differences between measures in the clinical group, which was less
homogeneous, were larger.
Clinically, the differences in differences between measures within each group do not
necessarily imply that one is “better” than another to distinguish between groups. Rather, these
differences may represent unique characteristics of the sample as well as differences in difficulty
and floor effects between measures. The clinical group in this case was relatively highfunctioning, and the performance of participants in the clinical group was greater than the mean
scaled score of 10 on several measures (specifically, WRAML2 Design Memory Recognition
and Picture Memory Recognition, WMS-IV Visual Reproduction I, and BVMT-R Immediate
Recall; Table 10).
While there is some evidence demonstrating that both groups of participants performed
differently on different measures, the overall evidence suggests that differences in performance
are greatest in the clinical group. In the clinical group, the largest differences between subtest
mean scaled scores were found between WRAML2 recognition measures and the other free
recall measures. Overall, participants in the clinical group performed better on the WRAML2
recognition measures than on WRAML2 Design Memory, WMS-IV Visual Reproduction II, and
BVMT-R Delayed Recall. Participants performed worse on BVMT-R Delayed Recall than on
WRAML2 Design Memory, WRAML2 Picture Memory, WRAML2 Design Memory
Recognition, and WRAML2 Picture Memory Recognition. No differences in performance were
found between WMS-IV Visual Reproduction (I and II) and the BVMT-R (Immediate and
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Delayed Recall). The average difference between mean scaled scores on each measure in the
clinical group was 1.6 scaled score points, ranging from .10 (WRAML2 Design Memory vs.
WMS-IV Visual Reproduction I) to 4.9 (WRAML2 Picture Memory Recognition vs. WMS-IV
Visual Reproduction II). The most interesting finding is the poorer overall performance of the
clinical group on the BVMT-R, particularly the Delayed Recall trial, as compared to the other
measures. On the other hand, pair-wise comparisons between measures in the control group did
not reveal any significant differences in mean scaled scores on any of the measures for which
scaled scores were derived. Clinically, these results suggest that while the BVMT-R is not
equivalent to WRAML2 measures in the memory-impaired group, it is equivalent to WMS-IV
Visual Reproduction. In this case, the WRAML2 measures, especially WRAML2 Design
Memory (which is similar to WMS-IV Visual Reproduction and the BVMT-R in content and
response format), are different enough from the other measures that they may be considered
useful additions to a clinical battery when time permits.
Finally, WMS-IV and BVMT-R recognition measures were compared separately, and
results indicate that the WMS-IV Visual Reproduction recognition trial may be useful on its own
to classify normal from impaired participants. However, its use is limited by the fact that it
requires the prior administration of the full WMS-IV Visual Reproduction subtest (I and II).
Conclusions/Implications
Taken overall, the results of this study support the use of WRAML2 Design Memory in
addition to either WMS-IV Visual Reproduction (I and II, along with Visual Reproduction
Recognition) or the BVMT-R (Immediate and Delayed, along with Recognition). Each of these
measures can be used independently to diagnose MCI or AD and document memory weaknesses.
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Participants in both groups performed relatively similarly on WMS-IV Visual Reproduction and
on the BVMT-R. The results of this study do not provide any empirical reason to suggest that
either one is “better” than the other; they are therefore “equivalent.” On the other hand,
WRAML2 measures, especially WRAML2 Design Memory, demonstrated unique measurement
characteristics that may make it a useful additions to existing test batteries. Empirically,
WRAML2 Design Memory provides additional variability in scores at lower levels of
performance, which may make it more reliable across a wider range of patients who may be
more severely impaired than participants in the present study. For example, Perri, Serra,
Carlesimo, and Caltagirone (2007) found that the participants who converted to AD from
amnestic MCI (aMCI) performed worse on visual memory measures than those who did not
convert. Therefore, subtle differences in test scores may be useful in making prognostic
judgments, and the lower floor of WRAML2 measures may make such decisions more accurate.
Clinically, WRAML2 Design Memory was easier and faster to administer and score than WMSIV Visual Reproduction despite the similarities in content between the two measures.
Certain measures were found to have different measurement characteristics than other
similar measures in the overall sample. The differences emerged primarily in the clinical group,
where mean scaled scores were higher for the WRAML2 delayed recognition measures than for
the WMS-IV and BVMT-R delayed recall measures. This finding is not surprising, given the fact
that the WRAML2 delayed recognition measures use a binary yes-no response format, increasing
the influence of chance (and “lucky guesses”) on a participant’s total score. Results confirm the
fact that recall tasks are generally more difficult than recognition tasks. All measures
demonstrated large differences in mean scaled scores between the clinical group and the control
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group and between the clinical group and normative samples, suggesting that any given measure
can be useful on its own. The differences in the clinical group suggest that when impairment is
present, WMS-IV and BVMT-R delayed recall measures may overemphasize the impairment. In
addition, differences between WRAML2, WMS-IV, and BVMT-R delayed retrieval trials are
likely influenced by the fact that the WRAML2 uses recognition rather than recall to measure
delayed retrieval.
There may be a floor effect on the other measures (i.e., both clinical subgroups performed
equally poorly due to item difficulty or limited range with very low scores), once again
suggesting that the measurement characteristics of the WRAML2 measures may allow the
clinician to make more refined conclusions about degree of pathology. Further evaluation of this
finding is warranted, particularly because of the potential ecological utility of a real-world,
contextual visual recognition task such as Picture Memory.
The clinical group in this study was reasonably similar to the clinical groups in normative
studies, with the exception of level of education; the clinical group in this study was more highly
educated. While limited information is available about the nature of those samples in terms of
severity of impairment or stage of disease, the clinical group in this study was comprised almost
entirely of patients with early-stage AD or MCI due to AD. It is possible that the performance of
the clinical group on WRAML2 subtests, particularly WRAML2 Design Memory, demonstrates
a larger measurement floor for those measures, allowing for greater variability in scores at lower
levels of performance as the disease progresses. This finding may have been influenced by an
inflationary impact that commission errors can have on WRAML2 Picture Memory scores, but
the number and, therefore, the impact of commission errors was not evaluated in this study.
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Thus, when using such measures to document strengths and weaknesses rather than simply to
classify normal vs. impaired, WRAML2 subtests may provide a more sensitive measure of
weakness.
Anecdotally, WRAML2 Picture Memory appeared to be more enjoyable for those
participants who felt that they did poorly on other design recall tasks. Picture Memory does
possess face validity that may be clinically useful, given additional support for ecological
validity. Specifically, very few older adults are likely to be expected to recall abstract geometric
designs on a regular basis, while almost all adults must repeatedly identify and recognize details
and changes in their immediate visual environment. Picture Memory may better assess this
important cognitive ability, although this will require further ecological validity studies.
Other Useful Findings
Mean scaled scores for BVMT-R Immediate Recall and Delayed Recall were strongly
correlated in both groups. In terms of classifying normal from impaired, the Delayed trial
provides useful information about retention and recall, which is an important aspect of memory
evaluation, as differences between encoding, retention, and recall can aid in differential
diagnosis of underlying pathology (Budson et al., 2006). The strong correlation between
immediate and delayed recall on the BVMT-R is worthy of additional evaluation in future
studies.
In terms of recognition tasks, the WMS-IV Visual Reproduction Recognition raw score
was the best at differentiating normal from impaired. It is the only recognition task that used a
multiple-choice response format. Compared to yes/no recognition tasks, this measure likely
allows for a more normally distributed range of scores despite having fewer total items.
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Unfortunately, this measure can only be administered as part of the entire Visual Reproduction
subtest, so the advantages it provides are lost by the fact that a lengthy, difficult task with an
inadequate floor precedes it. Regarding the finding that a single false-positive on the BVMT-R
Recognition task is indicative of cognitive impairment, this may reflect inefficient response
inhibition in individuals with mild cognitive impairment (Wylie, Ridderinkhof, Eckerle, &
Manning, 2007).
Limitations
This study presents a number of limitations that may compromise generalizability of the
results. In general, lack of statistical power to detect differences between measures within groups
is likely. The study was powered to detect differences between groups, which tend to be greater
than .75 standard deviations in most normative studies. Differences in performance between
measures within each group were much smaller, and null hypothesis tests failed to detect
significance in all but a few cases. With sufficient power, it may have been possible to detect a
difference between measures. In that case, however, the differences would be small, and the
resources to detect them would increase exponentially. From a practical standpoint, then, it can
be cautiously concluded that any statistically significant differences between measures found
with a larger sample may have negligible clinical significance.
There is evidence to suggest that variability in neuropsychological test scores changes
with increasing dementia severity (Reckess, Varvaris, Gordon, & Schretlen, 2014). Demographic
variables such as age, education, and IQ strongly affect decisions about “normal” and “impaired”
(Leckliter, 1989), and SES can also have an impact on the initial clinical presentation of patients
with memory complaints (Qian, Schweizer, & Fischer, 2013). If someone does well on verbal
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memory but not on visual memory, or vice-versa, it may be due to differences in spatial skills
(Heilbronner, 1992). Visuospatial skills are often impaired in early AD (Iachini et al., 2009).
This was not considered in the analysis. Both the WRAML2 and the WMS-IV have optional
copy trials to identify potential visual-motor deficits, but these trials were not used in the present
study.
Executive functioning was not taken into consideration, but it stands to reason that it
would have an effect, given the possible differences in executive demand between measures
(Busch et al., 2005). In particular, performance on the BVMT-R may be more susceptible to
weaknesses in executive functioning, as stimuli are presented all at once on a large grid,
requiring more effort on the part of the examinee to plan and organize an encoding strategy.
Likewise, the effect of processing speed was not taken into consideration, despite some evidence
that differences in processing speed may influence performance on memory measures (Tam &
Schmitter-Edgecombe, 2013). While none of the responses on any of the measures is timelimited, stimuli are presented for only a short time (5-10 seconds), and the amount of visual
information presented varies from task to task; it is therefore possible that subtle processing
speed deficits may impair the examinee’s ability to rapidly and efficiently encode the varying
amounts of visual information depending on which measure is chosen.
Age, education, and IQ consistently influence performance on a broad range of
neuropsychological measures (Lezak et al., 2004). Due in part to the correlation between IQ and
level of education, the mean estimated premorbid IQ for the control group was significantly
greater than the population mean standard score of 100. Furthermore, because of a potential
WTAR ceiling effect (Spinks et al., 2009), there was limited variability in estimated premorbid
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IQ within the control group. Given the well-documented relationships that exist between level of
education and performance on a variety of neuropsychological tests (Lezak et al., 2004), this
homogeneity limits any conclusions that can be made from control group data or comparisons
between the control group and the clinical group, limiting generalizability of these results to
groups of patients who are generally younger and more highly educated.
Because the control group was selected from a convenience sample, control group and
clinical group participants were not matched in terms of demographic covariates or US Census
data. The results of this study can be generalized only to older adults with probable AD or MCI
and who match the demographic characteristics of this sample. The clinical group in this study
had a mean level of education that was slightly greater than the general population. All
participants were Caucasian. The control group was selected by convenience and is very unlikely
to be a valid representation of the typical person who presents for evaluation and does not
receive a diagnosis of Alzheimer’s disease.
Compared to normative studies, some correlations were stronger in the control group,
while others were weaker. This may be due in part to the homogeneity of the control group as
well as differences between the control group and normative samples in terms of demographic
variables. For example, the variability in scores on WRAML2 decreases as performance
decreases because of age (Sheslow & Adams, 2003), thereby inflating the relationship between
each score.
Both WRAML2 visual memory subtests and their recognition tasks were used, allowing
for Visual Memory and Visual Recognition index scores to be derived for the present study.
However, the BVMT-R does not use a subtest/index scoring paradigm, and only one visual
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memory subtest from the WMS-IV was used. Analyses were therefore conducted on subtest
scaled scores, which are less reliable than index scores (Adams & Reynolds, 2009).
Comprehensive memory tests such as the WRAML2 and the WMS-IV are typically interpreted
“top down,” first at the index level and then, if indicated, at the subtest level. The results of this
study are therefore limited by the use of scores that may not be as reliable as index scores.
Youngjohn, Larrabee, and Crook (1993) gathered normative data for the Revised Benton
Visual Retention Test (BVRT) and found strong negative correlations between age and BVRT
scores and strong positive correlations between education and BVRT scores. Rönnlund, Nyberg,
Backman, and Nilson (2005) note that cohort differences in educational attainment are the reason
for discrepancies between cross-sectional and longitudinal studies assessing the relationship
between cognition and age. Particularly in the last half-century, level of education has been
increasing, and this may partly be reflected in the sample—particularly in the control group, in
which the difference in age between the oldest and youngest participants was almost 30 years. As
mentioned above, the measure used to estimate premorbid IQ in this study (the WTAR) has a
low ceiling that limits accuracy in estimating higher levels of performance. Estimating
premorbid IQ is difficult in patients with degenerative neurological diseases. While an estimate
of premorbid IQ is usefully in clinical settings, the cross-sectional nature of this study may have
allowed for the use of a more reliable measure of current IQ to obtain better data, at least in the
control group.
It should be noted that the BVMT-R measures were included in the diagnostic process
that defined group membership. This may be why mean BVMT-R scaled scores were observed
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to be lower than any other scores in the clinical group. However, clinicians making the diagnoses
were blinded to the results of WRAML2 and WMS-IV measures.
The WRAML2 delayed visual memory subtests are recognition-only in format. It is
therefore possible that the higher scores observed with these recognition subtests were due to the
fact that recognition scores are likely artificially inflated by the 50% chance of accuracy afforded
by the binary-choice format used by the DM and PM Recognition subtests. Scaled scores correct
for this factor to a degree, but because the floor exists at 50% correct, there is less variability
possible in obtained low raw scores, and greater possibility of atypical results with smaller
samples.
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Appendix A
DSM-IV-TR Diagnostic Criteria for Dementia of the Alzheimer’s Type (DAT)

A. The development of multiple cognitive deficits manifested by both:
1. memory impairment (impaired ability to learn new information or to recall
previously learned information) and (2) one (or more) of the following
cognitive disturbances:
a. aphasia (language disturbance)
b. apraxia (impaired ability to carry out motor activities despite intact
motor function)
c. agnosia (failure to recognize or identify objects despite intact sensory
function)
d. disturbance in executive functioning (i.e., planning, organizing,
sequencing, abstracting).
B. The cognitive deficits in criteria A1 and A2 each cause significant impairment in
social or occupational functioning and represent a significant decline from a previous
level of functioning.
C. The course is characterized by gradual onset and continuing cognitive decline.
D. The cognitive deficits in criteria A1 and A2 are not due to any of the following:
1. other central nervous system conditions that cause progressive deficits in
memory and cognition (e.g., cerebrovascular disease, Parkinson's disease,
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Huntington's disease, subdural hematoma, normal-pressure hydrocephalus,
brain tumor)
2. systemic conditions that are known to cause dementia (e.g., hypothyroidism,
vitamin B or folic acid deficiency, niacin deficiency, hypercalcemia,
neurosyphilis, HIV infection)
3. substance-induced conditions.
E. The deficits do not occur exclusively during the course of a delirium.
F. The disturbance is not better accounted for by another Axis I disorder (e.g., major
depressive episode, schizophrenia).
Adapted from American Psychiatric Association (2000).
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Appendix B
NIA-AA Diagnostic Guidelines for Probable Alzheimer’s Disease

Dementia is diagnosed when there are cognitive or behavioral (neuropsychiatric) symptoms that:
1. Interfere with the ability to function at work or at usual activities; and
2. Represent a decline from previous levels of functioning and performing; and
3. Are not explained by delirium or major psychiatric disorder.

The cognitive or behavioral impairment involves a minimum of two of the following domains:
1. Impaired ability to acquire and remember new information
2. Impaired reasoning and handling of complex tasks, poor judgment
3. Impaired visuospatial abilities
4. Impaired language functions (speaking, reading, writing)
5. Changes in personality, behavior, or comportment

Probable AD dementia is diagnosed when the patient’s presentation meets criteria for dementia
and, in addition, has the following characteristics:
1. Insidious onset;
2. Clear-cut history of worsening of cognition by report or observation; and
3. The initial and most prominent cognitive deficits are evident on history and examination
in one of the following categories:
a. Amnestic presentation: impairment in learning and recall of recently learned
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information and evidence of cognitive dysfunction in at least one other cognitive
domain.
b. Nonamnestic presentations:
i. Language presentation: The most prominent deficits are in word-finding,
but deficits in other cognitive domains should be present.
ii. Visuospatial presentation: The most prominent deficits are in spatial
cognition, including object agnosia, impaired face recognition,
simultanagnosia, and alexia. Deficits in other cognitive domains should be
present.
iii. Executive dysfunction: The most prominent deficits are impaired
reasoning, judgment, and problem solving. Deficits in other cognitive
domains should be present.
4. The diagnosis of probable AD dementia should not be applied when there is evidence of
a. substantial concomitant cerebrovascular disease, defined by
i. a history of a stroke temporally related to the onset or worsening of
cognitive impairment; or
ii. the presence of multiple or extensive infarcts or severe white matter
hyperintensity burden; or
b. core features of Dementia with Lewy bodies other than dementia itself; or
c. prominent features of behavioral variant frontotemporal dementia; or
d. prominent features of semantic variant primary progressive aphasia or nonfluent/agrammatic variant primary progressive aphasia; or
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e. evidence for another concurrent, active neurological disease, or a nonneurological medical comorbidity or use of medication that could have a
substantial effect on cognition.
Adapted from McKhann et al. (2011).
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Appendix C
DSM-5 Diagnostic Criteria for Major and Mild Neurocognitive Disorders
Major Neurocognitive Disorder
A. Evidence of significant cognitive decline from a previous level of performance in one or
more cognitive domains (complex attention, executive function, learning and memory,
language, perceptual-motor, or social cognition) based on:
1. Concern of the individual, a knowledgeable informant, or the clinician that there has
been a significant decline in cognitive function; and
2. A substantial impairment in cognitive performance, preferably documented by
standardized neuropsychological testing or, in its absence, another quantified clinical
assessment.
B. The cognitive deficits interfere with independence in everyday activities (i.e., at a minimum,
requiring assistance with complex instrumental activities of daily living such as paying bills
or managing medications).
C. The cognitive deficits do not occur exclusively in the context of a delirium.
D. The cognitive deficits are not better explained by another mental disorder (e.g., major
depressive disorder, schizophrenia).

Minor Neurocognitive Disorder
A. Evidence of modest cognitive decline from a previous level of performance in one or more
cognitive domains (complex attention, executive function, learning and memory, language,
perceptual-motor, or social cognition) based on:
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1. Concern of the individual, a knowledgeable informant, or the clinician that there has
been a mild decline in cognitive function; and
2. A modest impairment in cognitive performance, preferably documented by
standardized neuropsychological testing or, in its absence, another quantified clinical
assessment.
B. The cognitive deficits do not interfere with capacity for independence in everyday activities
(i.e., complex instrumental activities of daily living such as paying bills or managing
medications are preserved, but greater effort, compensatory strategies, or accommodation
may be required).
C. The cognitive deficits do not occur exclusively in the context of a delirium.
D. The cognitive deficits are not better explained by another mental disorder (e.g., major
depressive disorder, schizophrenia).

Major or Mild Neurocognitive Disorder Due to Alzheimer’s Disease
A. The criteria are met for major or mild neurocognitive disorder.
B. There is insidious onset and gradual progression of impairment in one or more cognitive
domains (for major neurocognitive disorder, at least two domains must be impaired).
C. Criteria are met for either probable or possible Alzheimer’s disease as follows:

For major neurocognitive disorder: Probable Alzheimer’s disease is diagnosed if either of the
following is present; otherwise, possible Alzheimer’s disease should be diagnosed.
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1. Evidence of a causative Alzheimer’s disease genetic mutation from family history or
genetic testing.
2. All three of the following are present:
a. Clear evidence of decline in memory and learning and at least one other
cognitive domain (based on detailed history or serial neuropsychological
testing).
b. Steadily progressive, gradual decline in cognition, without extended plateaus.
c. No evidence of mixed etiology (i.e., absence of other neurodegenerative or
cerebrovascular disease, or another neurological, mental, or systemic disease
or condition likely contributing to cognitive decline).

For mild neurocognitive disorder: Probable Alzheimer’s disease is diagnosed if there is
evidence of a causative Alzheimer’s disease genetic mutation from either genetic testing or
family history. Possible Alzheimer’s disease is diagnosed if there is no evidence of a
causative Alzheimer’s disease genetic mutation from either genetic testing or family history,
and all three of the following are present:
1. Clear evidence of decline in memory and learning.
2. Steadily progressive, gradual decline in cognition, without extended plateaus.
3. No evidence of mixed etiology (i.e., absence of other neurodegenerative or
cerebrovascular disease, or another neurological or systemic disease or condition
likely contributing to cognitive decline).
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The disturbance is not better explained by cerebrovascular disease, another
neurodegenerative disease, the effects of a substance, or another mental, neurological, or
systemic disorder.
Adapted from American Psychiatric Association (2013).
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Appendix D
Informed Consent to Participate in Clinical Research

Principal Investigator: Guy B. deBros, MA
The Memory Clinic
357 Shields Drive
Bennington, VT 05201
(802) 447-1409 x34
guy@memorydoc.org

I, ______________________________, hereby consent to participate in The Memory Clinic’s
research on visual memory. I understand that testing will be conducted in conjunction with my
diagnostic evaluation. I understand that the results of my evaluation will be used as part of the
study. I understand that no identifiable information will be available within the study. I
understand that all analyses will be conducted on aggregate data. I understand that there is
minimal risk involved (i.e., fatigue due to an additional 5 to 10 minutes of testing). I understand
that I may withdraw my consent to participate at any time and for any reason without any risk of
consequences and without fear of jeopardizing my clinical relationship with The Memory Clinic.
I understand that if I choose to withdraw my consent, my data will be removed from any and all
analyses being conducted for the purpose of the study; however, I understand that withdrawal of
consent to participate does not mean that records related to my clinical relationship with the
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Memory Clinic will be destroyed. I understand that I may contact The Memory Clinic if I have
any questions or concerns.

______________________________

______________________________

Printed Name of Participant

Signature of Participant
or Legally Authorized Representative

______________________________

______________________________

Printed Name of Person Conducting

Printed Name of Person Conducting

Informed Consent Discussion (or P.I.)

Informed Consent Discussion (or P.I.)
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Appendix E
Curriculum Vitae
Guy B. deBros
The Memory Clinic
357 Shields Drive
Bennington, VT 05201
(802) 447-1409
guy@memorydoc.org
Education
2009 – Present

George Fox University, Newberg, OR
Graduate Dept. of Clinical Psychology: APA Accredited PsyD Program
Anticipated date of PsyD degree: November, 2014

2007 – 2009

George Fox University, Newberg, OR
Graduate Dept. of Clinical Psychology: APA Accredited PsyD Program
Master of Arts, Clinical Psychology

2001 – 2006

Tufts University, Medford, MA
Bachelor of Arts, Psychology/Clinical

Clinical Experience
2012 – Present

Clinical Psychology Doctoral Internship
The Memory Clinic, Bennington, VT
Administered, scored, and interpreted neuropsychological tests. Participated in
patient and caregiver interviews, diagnostic discussions, and case conferences.
Prepared draft reports. Provided caregiver supportive counseling. Assisted
with data entry and database management.
Supervisors: Cynthia Murphy, PsyD, MBA, Diana E. Michalczuk, PsyD, and
Paul R. Solomon, PhD

2011 – 2012

Clinical Psychology Practicum
Providence Medical Group, Sherwood, OR
Provided behavioral health consultation services, brief cognitive-behavioral
and solution-focused interventions, and psychoeducation in a suburban
primary care clinic. Collaborated with staff to clarify diagnoses and make
pharmacological and referral recommendations. Administered and interpreted
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brief symptom checklists and screeners as needed.
Supervisor: Marie-Christine Rutter-Goodworth, PhD
2010 – 2012

Clinical Psychology Practicum
Sundstrom Clinical Services, Clackamas, OR
Provided psychoeducational and neuropsychological evaluation services in a
child and adult outpatient group practice. Presenting problems included autism
spectrum disorders, multiple sclerosis, ADHD, disruptive behavior disorders,
depression and anxiety, as well as adjustment and personality disorders.
Participated in weekly group didactic sessions. Weekly individual supervision
with occasional group case discussions.
Supervisor: Paul E. Sundstrom, EdD

2009 – 2010

Clinical Psychology Practicum
Square Peg Psychological, Gladstone, OR
Provided school counseling services to female and male secondary students in
a private high school setting. Provided consultation services to school staff.
Presented didactic seminars to health and psychology classes. Co-facilitated a
weekly skill-building group dealing with stress and anxiety. Weekly
individual and group supervision.
Supervisor: Denise López Haugen, PsyD

2009 – 2010

Clinical Psychology Practicum
George Fox University Behavioral Health Clinic, Newberg, OR
Provided several dementia screening assessments and reports for patients
referred by a psychiatrist at a local hospital. Presenting problems included
closed-head injury, CVA, and multiple sclerosis. Supervision received for
each referral.
Supervisor: Joel Gregor, PsyD

2009 – 2010

Clinical Psychology Practicum
St. Paul School District, St. Paul, OR
Provided several comprehensive psychoeducational assessments and reports at
the high school and kindergarten levels. Participated in IEP meetings with
school staff and family members. Provided feedback to school staff regarding
possible interventions. Supervision received for each referral.
Supervisor: Elizabeth Hamilton, PhD

2008 – 2009

Clinical Psychology Practicum
Multnomah County Department of Corrections, Portland, OR
Provided psychological services to female and male adult inmates housed in a
medium-security county jail. Direct services included individual
psychotherapy (short- and long-term), psychological evaluations using
personality, cognitive-intellectual, and neuropsychological measures,
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consultations with medical staff, and recommendations for treatment
placement. Co-facilitated weekly didactic group psychotherapy focusing on
diverse topics including stress, anger management, relaxation, thinking skills,
and assertiveness training. Presenting problems included multiple Axis I and
II disorders and severe mental illness. Weekly individual and group
supervision.
Supervisor: Stephen Huggins, PsyD, CCHP
2007 – 2008

Clinical Psychology Pre-Practicum
George Fox University, Newberg, OR
Provided outpatient psychotherapy services to female and male undergraduate
students. Responsibilities included intake interviews, personality assessment,
diagnosis, treatment planning, and individual psychotherapy. Monitored
progress through video tape reviews and presented cases to supervision group.
Supervisors: Mary Peterson, PhD, Licensed Clinical Psychologist and
Associate Director of Clinical Training; Lisa A. Jones, MA, Clinical
Psychology Graduate Student

2006 – 2007

Assistant Crisis Counselor
S.E.E.K. Program, John F. Kennedy Elementary School, Somerville, MA
Paid position providing behavioral interventions to female and male special
education students in a public elementary school. Responsibilities included
assisting students with behavioral goals, providing support and intervening
during behavioral crises, participating in weekly staff meetings, and
supervising classroom activities alongside school staff.

2005 – 2006

Clinical Psychology Undergraduate Practicum
S.E.E.K. Program, John F. Kennedy Elementary School, Somerville, MA
Provided behavioral therapy services to female and male special education
students in a public elementary school. Responsibilities included assisting
students with behavioral goals, providing support and intervening during
behavioral crises, participating in weekly staff meetings, and supervising
classroom and extracurricular activities in conjunction with school staff.
Weekly individual supervision.
Supervisor: Wanda Finigian, MEd, Licensed Learning Specialist

2005 – 2007

Emergency Medical Technician – Basic
EasCare Ambulance Service, Boston, MA
Provided emergency medical services and medical transportation to the
Greater Boston area. Responsibilities included responding to life-threatening
and non-life-threatening emergencies in a variety of settings and situations,
monitoring basic vital signs before and during transportation to hospitals and
other medical facilities, coordinating patient care with receiving providers,
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and assisting paramedics and fire department workers during single- and
multiple-casualty incidents.
2004 – 2005

Emergency Medical Technician – Basic
Professional Ambulance Service, Cambridge, MA
Provided emergency medical services and medical transportation to the City
of Cambridge by ambulance. Responsibilities included responding to lifethreatening and non-life-threatening emergencies in a variety of settings and
situations, monitoring basic vital signs before and during transportation to
hospitals and other medical facilities, coordinating patient care with receiving
providers, and assisting paramedics and fire department workers during
single- and multiple-casualty incidents.

2001 – 2004

Anesthesia Technician
Massachusetts General Hospital, Boston, MA
Provided supply and equipment support to anesthesiologists and nurse
anesthetists in a suite of approximately 50 operating rooms. Responsibilities
included cleaning and maintaining equipment, restocking supplies before and
during operations, and assisting anesthesiologists and nurse anesthetists as
needed during procedures.

Research and Professional Presentations
Solomon, T. M., deBros, G. B., Budson, A. E., Mirkovic, N., Murphy, C. A., & Solomon, P. R.
(2014). Correlational analysis of five commonly used measures of cognitive functioning
and mental status: An update. American Journal of Alzheimer’s Disease and Other
Dementias, 29(8), 718-722.
deBros, G. B., & Solomon, T. M. (2014, February). The Montreal Cognitive Assessment
(MoCA) is superior to the Mini-Mental State Examination (MMSE) in differentiating
MCI from normal healthy aging in patients with subjective memory complaints.
Presentation at the 42nd Annual Meeting of the International Neuropsychological
Society, Seattle, WA.
Solomon, T. M., deBros, G. B., Mirkovic, N., Murphy, C. A., & Solomon, P. R. (2014,
February). Analysis of five commonly used measures of cognitive functioning and mental
status. Presentation at the 42nd Annual Meeting of the International Neuropsychological
Society, Seattle, WA.
Solomon, T. M., Budson, A. E., deBros, G. B., Murphy, C. A., & Solomon, P. R. (2014,
February). A proof of concept study for a randomized, double-blind, placebo-controlled,
parallel group, efficacy study of Alpha BRAIN™ administered orally. Presentation at the
42nd Annual Meeting of the International Neuropsychological Society, Seattle, WA.
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Solomon, T. M., deBros, G. B., Mirkovic, N., Murphy, C., & Solomon, P. R. (2013, April).
Relationships between commonly used measures of cognitive and functional status.
Presentation at the Stanley Cobb Assembly of the Boston Society of Neurology and
Psychiatry, Boston, MA.
Adams, W., & deBros, G. B. (2010, August). A comparison of visual memory in Chinese and
US children. Presentation at the 118th Annual Convention of the American Psychological
Association, San Diego, CA.
deBros, G. B., Jurecska, D. E., Millkey, A. M., & Peterson, M. (2010, May). The Malingered
Ignorance of Legal Knowledge Test (MILK): A brief measure of forensic symptom
validity. Presentation at the 10th Annual Conference of the International Association of
Forensic Mental Health Services, Vancouver, BC, Canada.
University Involvement
Fall, 2011

Co-Lecturer
George Fox University, Newberg, OR
General Psychology
Prepared, co-taught, and managed an introductory psychology course as part
of the graduate-level Academic Careers course.
Supervisor: Kathleen Gathercoal, PhD

2010 – 2012

Graduate Teaching Assistant
Graduate Dept. of Clinical Psychology, George Fox University, Newberg, OR
Neuropsychological Assessment
Coordinated class materials, taught and demonstrated the use of several
neuropsychological tests.
Supervisor: Wayne Adams, PhD, ABPP

Professional Affiliations
2009 – Present

International Neuropsychological Society
Student Member

2009 – Present

National Academy of Neuropsychology
Student Member

2008 – Present

American Psychological Association
Graduate Student Affiliate

